CATSHL Syndrome

Mendelian MONDO:0012504 Pathograph 17 Show in embeddings browser FGFR3-related skeletal dysplasia

CATSHL syndrome is an ultra-rare skeletal dysplasia caused by germline loss of FGFR3 function. FGFR3 normally restrains chondrocyte proliferation and hypertrophy in the growth plate, so losing that restraint produces the mirror image of the FGFR3 gain-of-function chondrodysplasias: tall stature and overgrown long bones and vertebrae rather than short-limbed dwarfism. The named features are camptodactyly, tall stature, scoliosis and congenital or early-onset sensorineural hearing loss; developmental delay, microcephaly, pectus deformity and solitary osteochondromas occur in a subset. The hearing loss is not a secondary consequence of the skeletal disease but a separate requirement for FGFR3 in the cochlea, where it is needed for pillar cells of the organ of Corti to differentiate. Fewer than about 35 individuals have been reported, in three families.

Ask OpenScientist

Ask a research question about CATSHL Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
7
Pathophys.
16
Phenotypes
3
Gaps
17
Pathograph
1
Genes
3
Variants
4
Medical Actions
3
Differentials
4
Models
3
References
1
Deep Research
🏷

Classifications

ISDS Skeletal Nosology
fgfr3 chondrodysplasia
👪

Inheritance

2
Autosomal dominant HP:0000006
The two heterozygous alleles reported to date, p.Arg621His and p.Arg621Cys, both segregate as autosomal dominant traits - across four generations of a Utah pedigree and between a father and his daughter in an Italian family.
Autosomal dominant inheritance
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"we screened FGFR3 and subsequently identified a heterozygous missense mutation that is predicted to cause a p.R621H substitution in the tyrosine kinase domain and partial loss of FGFR3 function."
A heterozygous allele segregating through a multigeneration pedigree establishes dominant transmission.
Autosomal recessive HP:0000007
One consanguineous Egyptian family carries a different allele, p.Thr546Lys, in the homozygous state, with unaffected heterozygous relatives. So CATSHL is not a single inheritance mode: the two reported Arg621 substitutions act dominantly, and this one does not act at all in the heterozygous state. Whether that difference is a property of the residue or of the substitution has not been tested.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:24864036 SUPPORT Human Clinical
"We report the phenotype and underlying molecular abnormality in two brothers, born to first cousin parents."
Affected sibs of consanguineous parents carrying the variant homozygously indicate recessive inheritance for this allele.
?

Discussions and Knowledge Gaps

3
Why do CATSHL patients have craniofacial abnormalities and microcephaly when Fgfr3-deficient mice have no craniofacial phenotype at all?
HUMAN MODEL MISMATCH catshl_craniofacial_model_mismatch
Attached to
phenotypes#Microcephaly phenotypes#High Palate phenotypes#Wormian Bones phenotypes#Developmental Delay and Intellectual Disability
The mouse reproduces the two features that made it the candidate model - skeletal overgrowth and deafness - and reproduces them well. It does not reproduce microcephaly, high palate or wormian bones, which are recorded in the human families. This is not a gap in evidence but a discordance between species: the measurement has been made in the mouse and the answer is negative. The zebrafish does show microcephaly and delayed suture closure, which makes the mouse the outlier rather than the human, but zebrafish craniofacial development is far enough from human that it cannot settle the mechanism. Until it is resolved, the craniofacial and neurodevelopmental features of CATSHL have no model system that both shows them and is close enough to human to interpret.
Show evidence (2 references)
PMID:32641982 SUPPORT Model Organism
"The reason for the discrepant in the craniofacial phenotypes between mouse model and patients remains to be studied."
The authors state the mismatch explicitly and record it as unresolved. Quoted as written, including the grammatical slip in the original.
PMID:32641982 SUPPORT Model Organism
"craniofacial bone malformation with microcephaly and delayed closure of cranial sutures"
Establishes that the zebrafish, unlike the mouse, does show the craniofacial phenotype.
Do the Arg621 alleles act as dominant negatives, and if so does the mutant receptor actually inhibit its wild-type partner?
KNOWLEDGE GAP catshl_dominant_negative_untested
Attached to
pathophysiology#FGFR3 Kinase-Domain Loss of Function
The dominant-negative model is the only explanation on offer, and the arguments against haploinsufficiency are good ones. But the positive claim has never been tested: nobody has shown that mutant FGFR3 heterodimerises with the wild-type receptor and suppresses its kinase activity. The evidence offered is that mutant and wild-type transcripts are expressed at comparable levels and both proteins reach the membrane, which is consistent with a dominant negative and equally consistent with a simple hypomorph whose threshold effects differ between tissues. The distinction matters for whether the two Arg621 substitutions and the Thr546Lys allele share one mechanism.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"For several reasons, it is unlikely that the loss of function caused by p.R621H results from haploinsufficiency."
The authors' own framing of the mechanism as an inference from exclusion rather than a demonstration.
Why does either too little or too much FGFR3 signaling cause deafness?
KNOWLEDGE GAP catshl_bidirectional_cochlear_failure
Attached to
pathophysiology#Failure of Cochlear Pillar Cell Differentiation
Loss of Fgfr3 abolishes pillar cell differentiation; the activating Y367C allele produces fully penetrant deafness with an increased number of pillar or modified supporting cells. The organ of Corti therefore fails in both directions from an intermediate optimum, which is unusual and is not explained by a simple dose-response model of the receptor. Whether the two deafnesses share a final common lesion or are distinct failures of the same patterning step is unknown, and the answer would constrain how the human hearing loss is expected to progress.
Show evidence (2 references)
PMID:19073250 SUPPORT Model Organism
"The inner ear defect is mainly associated with an increased number of pillar cells or modified supporting cells in the organ of Corti."
Shows the gain-of-function receptor producing the opposite cellular change in the same structure, which is what makes the bidirectional failure a real question rather than a rhetorical one.
PMID:19073250 SUPPORT Model Organism
"The mutant Fgfr3(Y367C/+) mice exhibit fully penetrant deafness with a significantly elevated auditory brainstem response threshold for all frequencies tested."
Establishes that the activating allele also causes deafness, not merely a cellular change.
⚙

Pathophysiology

7
FGFR3 Kinase-Domain Loss of Function
A germline missense substitution in the FGFR3 tyrosine kinase domain reduces receptor kinase activity. The recurrent dominant allele replaces Arg621 in the catalytic loop, the residue that positions the transferred phosphate and is invariant across the tyrosine kinase superfamily; the recessive allele replaces Thr546 elsewhere in the same domain. The dominant alleles are unlikely to act by haploinsufficiency - the original authors give three reasons, of which the strongest is that heterozygous Fgfr3-null mice are normal - and a dominant-negative heterodimer with the wild-type receptor is the proposed alternative. That proposal has not been tested biochemically in a CATSHL allele, so the entry treats the direction of effect as established and the dominant-negative mechanism as the working model rather than a finding.
FGFR3 hgnc:3690 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves FGFR3 (hgnc:3690), qualified as loss of function. hgnc:3690 is a gene from the HUGO Gene Nomenclature Committee. ⇓ LOSS OF FUNCTION
Genetic context FGFR3 hgnc:3690 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns FGFR3 (hgnc:3690). hgnc:3690 is a gene from the HUGO Gene Nomenclature Committee. allele_type: MISSENSE variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: PARTIAL_LOSS_OF_FUNCTION
Describes the two dominant Arg621 alleles, which is the common genotype. PARTIAL_LOSS_OF_FUNCTION rather than LOSS_OF_FUNCTION because the founding report describes the substitution as causing partial loss of FGFR3 function, and DOMINANT_NEGATIVE is deliberately not used even though it is the proposed mechanism - it has never been demonstrated, which is what the catshl_dominant_negative_untested discussion is about. The p.Thr546Lys allele is homozygous and is not covered by this block; its zygosity is recorded on the variant and in the inheritance section.
fibroblast growth factor receptor activity GO:0005007 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased fibroblast growth factor receptor activity (GO:0005007). GO:0005007 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Reduced MAPK/ERK Output in Growth Plate Chondrocytes Reduced receptor kinase activity lowers the inhibitory signal FGFR3 normally sends into the growth plate.
Failure of Cochlear Pillar Cell Differentiation The same receptor is required in cochlear supporting cells, so the cochlear arm branches at the receptor rather than downstream of the skeletal pathway.
Show evidence (3 references)
PMID:17033969 SUPPORT DIRECT Human Clinical
"R621 is located in the catalytic loop of the tyrosine kinase domain of FGFR3, and it is invariant in the tyrosine kinase superfamily"
Locates the recurrent dominant substitution in the catalytic machinery of the kinase, which is why it reduces activity.
PMID:17033969 SUPPORT INDIRECT Human Clinical
"These observations suggest that p.R621H might, instead, cause loss of FGFR3 function by a dominant negative mechanism."
The authors' own proposal for how a heterozygous allele produces loss of function. Graded INDIRECT because the sentence is an inference from the arguments against haploinsufficiency, not a demonstration of heterodimer inhibition.
PMID:24864036 SUPPORT DIRECT Human Clinical
"This is the first report of a homozygous loss-of-function mutation in FGFR3 in human that results in a skeletal overgrowth syndrome."
Independent confirmation that FGFR3 loss of function, not gain, produces the overgrowth phenotype.
Reduced MAPK/ERK Output in Growth Plate Chondrocytes
In the proliferative and prehypertrophic growth plate, ligand-activated FGFR3 signals through MAPK/ERK to inhibit chondrocyte proliferation and hypertrophic differentiation. This is the step that makes FGFR3 a negative regulator of bone growth, and it is what a loss-of-function allele removes. The direction is the point: every other FGFR3 skeletal disorder in this knowledge base sits at the opposite end of the same axis.
Growth plate chondrocyte CL:1000217 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Growth plate chondrocyte, annotated with growth plate cartilage chondrocyte (CL:1000217). CL:1000217 is a cell type from the Cell Ontology.
fibroblast growth factor receptor signaling pathway GO:0008543 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased fibroblast growth factor receptor signaling pathway (GO:0008543). GO:0008543 is a biological process from the Gene Ontology. ↓ DECREASED ERK1 and ERK2 cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Disinhibited Chondrocyte Proliferation and Hypertrophy
Derepressed Indian Hedgehog Signaling MEK inhibition alone raises Ihh expression in Fgfr3-deficient chondrocytes, placing the hedgehog arm downstream of the drop in MAPK output.
Show evidence (2 references)
PMID:8601314 SUPPORT DIRECT Model Organism
"Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis."
States the negative-regulator role whose removal is this node.
PMID:26091072 SUPPORT DIRECT Model Organism
"The lesions showed decreased extracellular signal-regulated kinase (ERK) activity and increased Indian hedgehog (IHH) expression."
Measures the fall in ERK activity in cartilage lacking Fgfr3, which is the specific effector claim of this node.
Derepressed Indian Hedgehog Signaling
Loss of FGFR3 raises Indian hedgehog expression in growth-plate cartilage, and inhibiting hedgehog signaling reduces the resulting lesions. The confidence is PROVISIONAL rather than established because the whole of this arm rests on mouse and zebrafish work; no CATSHL patient tissue has been examined for hedgehog pathway activity, and the human disease has not been shown to run through this step.
smoothened signaling pathway GO:0007224 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased smoothened signaling pathway (GO:0007224). GO:0007224 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Chondrocyte-specific postnatal Fgfr3 knockout mouse Mouse measures The model is where the raised IHH and lowered ERK were actually measured.
fgfr3 knockout zebrafish Zebrafish recapitulates Confirms raised IHH in a second species and adds canonical Wnt/beta-catenin as a parallel derepressed pathway, with partial phenotypic rescue by a Wnt inhibitor.
Downstream
Chondroma-like Lesion Formation
Show evidence (2 references)
PMID:26091072 SUPPORT DIRECT Model Organism
"Importantly, treatment with an inhibitor of IHH signaling reduced the occurrence of chondroma-like lesions in Fgfr3-deficient mice."
A rescue experiment, which is stronger than the correlation - blocking the pathway reduces the phenotype it is proposed to cause.
PMID:32641982 SUPPORT DIRECT Model Organism
"we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up-regulated canonical Wnt/β-catenin signaling, and pharmacological inhibition of Wnt/β-catenin could partially alleviate the phenotypes of fgfr3 mutants."
A second species reaching the same hedgehog result, and adding canonical Wnt as a parallel derepressed pathway.
Disinhibited Chondrocyte Proliferation and Hypertrophy
Without the FGFR3 brake, the proliferative and hypertrophic zones of the growth plate expand and chondrocytes continue to divide and enlarge for longer than they should. This is the cellular event that converts a receptor defect into extra bone length.
Proliferating growth plate chondrocyte CL:1000217 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Proliferating growth plate chondrocyte, annotated with growth plate cartilage chondrocyte (CL:1000217). CL:1000217 is a cell type from the Cell Ontology. Hypertrophic chondrocyte CL:0000743 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Hypertrophic chondrocyte (CL:0000743). CL:0000743 is a cell type from the Cell Ontology.
growth plate cartilage chondrocyte proliferation GO:0003419 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased growth plate cartilage chondrocyte proliferation (GO:0003419). GO:0003419 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Endochondral Bone and Vertebral Overgrowth
Show evidence (1 reference)
PMID:8601314 SUPPORT DIRECT Model Organism
"This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate."
Directly reports the cellular expansion this node asserts.
Endochondral Bone and Vertebral Overgrowth
Extra growth-plate output lengthens the long bones and the vertebral bodies. Only bones formed by endochondral ossification are affected, which is why the radiographic signature is tall vertebral bodies and long tubular shafts rather than a generalized bone abnormality. Overlong vertebral bodies are also the mechanical origin of the scoliosis, so the spinal deformity is a consequence of the overgrowth rather than an independent feature.
endochondral bone growth GO:0003416 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased endochondral bone growth (GO:0003416). GO:0003416 is a biological process from the Gene Ontology. ↑ INCREASED
growth plate cartilage UBERON:0004129 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in growth plate cartilage (UBERON:0004129). UBERON:0004129 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Fgfr3-null mouse Mouse recapitulates Skeletal overgrowth of long bones and vertebrae with kyphosis and scoliosis, matching the human radiographic pattern.
Spider lamb syndrome sheep Sheep partially recapitulates Heterozygous animals have modestly increased long-bone length; homozygotes have elongated limbs, spinal deformity and limb flexion contractures.
Show evidence (3 references)
PMID:8601314 SUPPORT DIRECT Model Organism
"We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth."
Establishes enhanced and prolonged endochondral growth as the tissue-level result of losing the receptor.
PMID:17033969 SUPPORT DIRECT Human Clinical
"Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts"
The human radiographic counterpart of the mouse overgrowth phenotype.
PMID:17033969 SUPPORT DIRECT Human Clinical
"These findings indicate that abnormal FGFR3 signaling can cause human anomalies by promoting as well as inhibiting endochondral bone growth."
States the bidirectional axis that makes this entry the counterpart of the achondroplasia group.
Chondroma-like Lesion Formation
Disordered growth plates lacking FGFR3 generate enchondroma- and osteochondroma-like cartilage lesions in mice. Several members of the Utah pedigree had a solitary osteochondroma of the femur, tibia or a phalanx, which is the human observation this node is anchored to. The link between the two is not established: the human lesions are solitary and were not examined for hedgehog activity, while the mouse lesions are multiple and mechanistically dissected, so the node records a plausible correspondence rather than a demonstrated one.
Animal models
Chondrocyte-specific postnatal Fgfr3 knockout mouse Mouse recapitulates Multiple enchondroma- and osteochondroma-like lesions adjacent to disordered growth plates, with reduced ERK and raised IHH, and fewer lesions when hedgehog signaling is blocked.
Show evidence (2 references)
PMID:26091072 SUPPORT DIRECT Model Organism
"we found that postnatal chondrocyte-specific Fgfr3 deletion induced multiple chondroma-like lesions, including enchondromas and osteochondromas, adjacent to disordered growth plates."
The model-system observation of cartilage lesions arising from Fgfr3 loss.
PMID:17033969 SUPPORT INDIRECT Human Clinical
"Several affected individuals had a single osteochondroma of the femur, the tibia, or a phalanx"
The human counterpart. Graded INDIRECT because the report records the lesions without linking them to FGFR3 signaling in those individuals.
Failure of Cochlear Pillar Cell Differentiation
FGFR3 is expressed in the cochlear supporting cells that become pillar cells, and losing it prevents pillar cell differentiation and tunnel of Corti formation, producing sensorineural deafness with a structurally normal middle and inner ear on imaging. This explains an otherwise puzzling feature of the clinical picture: the hearing loss is sensorineural and profound while CT and MRI are normal, because the defect is at the level of cell identity within the organ of Corti rather than of gross morphogenesis.
Cochlear pillar cell CL:1000191 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cochlear pillar cell, annotated with pillar cell (CL:1000191). CL:1000191 is a cell type from the Cell Ontology.
inner ear morphogenesis GO:0042472 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal inner ear morphogenesis (GO:0042472). GO:0042472 is a biological process from the Gene Ontology. ⚠ ABNORMAL
organ of Corti UBERON:0002227 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in organ of Corti, annotated with spiral organ of cochlea (UBERON:0002227). UBERON:0002227 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Fgfr3-null mouse Mouse recapitulates Pillar cells fail to differentiate and the tunnel of Corti does not form, producing profound deafness - the cellular lesion the human sensorineural hearing loss is attributed to.
Show evidence (2 references)
PMID:8630492 SUPPORT DIRECT Model Organism
"Inner ear defects include failure of pillar cell differentiation and tunnel of Corti formation and result in profound deafness."
The cellular lesion behind the hearing loss, demonstrated in the null mouse.
PMID:17033969 SUPPORT INDIRECT Human Clinical
"Computed tomography and magnetic resonance imaging revealed that the brain, middle ear, and inner ear were structurally normal."
Normal imaging alongside sensorineural loss is consistent with a cellular-differentiation defect rather than a structural malformation. Graded INDIRECT because normal imaging excludes alternatives rather than demonstrating the pillar cell defect in patients.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for CATSHL Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Head and Neck 3
High Palate HP:0000218 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is High palate (HP:0000218). HP:0000218 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32641982 SUPPORT Human Clinical
"Other clinical features of CATSHL syndrome include microcephaly, wormian skull bones, a high palate, pectus excavatum"
The zebrafish paper's introduction enumerates the human clinical features drawn from the three case reports. Graded HUMAN_CLINICAL because the sentence describes patients, not the fish. No frequency band: the sentence is a feature list with no denominators.
Wormian Bones HP:0002645 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Wormian bones (HP:0002645). HP:0002645 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32641982 SUPPORT Human Clinical
"microcephaly, wormian skull bones, a high palate"
Same feature list. Graded HUMAN_CLINICAL for the same reason; no denominator, so no frequency band.
Microcephaly HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"several of these had microcephaly (head circumference <2nd percentile)"
Documents microcephaly with its measurement threshold. No frequency band - "several" of the 12 delayed individuals gives no usable denominator.
Limbs 1
Arachnodactyly HP:0001166 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arachnodactyly (HP:0001166). HP:0001166 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24864036 SUPPORT Human Clinical
"The clinical picture is characterized by tall stature and severe skeletal abnormalities leading to inability to walk, with camptodactyly, arachnodactyly, and scoliosis."
Reports arachnodactyly in the biallelic family.
Musculoskeletal 3
Camptodactyly VERY_FREQUENT HP:0012385 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Camptodactyly (HP:0012385). HP:0012385 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"was present in 18 (90%) of 20 individuals, and 17 (85%) of 20 had hearing loss"
90% of genotyped individuals had camptodactyly, supporting VERY_FREQUENT.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"pectus abnormalities; and/or severe thoracolumbar kyphoscoliosis"
Records the severe end of the spinal phenotype.
Pectus Excavatum HP:0000767 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pectus excavatum (HP:0000767). HP:0000767 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Several had scoliosis and/or a pectus excavatum"
The primary report of the finding in the founding pedigree.
Nervous System 1
Developmental Delay and Intellectual Disability FREQUENT HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Of 20 individuals, 12 (60%) had developmental delay and/or mental retardation, and several of these had microcephaly (head circumference <2nd percentile)."
60% of 20 genotyped individuals falls in the 30-79% FREQUENT band.
Growth 1
Tall Stature VERY_FREQUENT HP:0000098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tall stature (HP:0000098). HP:0000098 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Adult height in males was >97th percentile in 5 of 5 men, with a mean height of 77 inches, and adult height in females was >75th percentile in 9 of 9 and >97th percentile in 8 of 9 women, with a mean height of 70 inches."
Gives per-sex counts above the 97th and 75th centiles, supporting a VERY_FREQUENT band.
Other 7
Camptodactyly of Toe HP:0001836 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Camptodactyly of toe (HP:0001836). HP:0001836 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Camptodactyly of the hands and/or feet"
Records foot involvement. No frequency is given because the published count pools hands and feet, so no toe-specific denominator exists.
Sensorineural Hearing Loss VERY_FREQUENT Progressive sensorineural hearing impairment HP:0000408 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive sensorineural hearing impairment (HP:0000408), qualified as course progressive. HP:0000408 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:17033969 SUPPORT Human Clinical
"On audiological exam, each tested individual had bilateral sensorineural hearing loss and absent otoacoustic emissions"
Establishes the sensorineural character and the absent otoacoustic emissions.
PMID:17033969 SUPPORT Human Clinical
"By report, the hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and ranged from mild to severe."
Supports both the congenital/early onset and the progressive course recorded in the qualifier.
Osteochondroma HP:0030431 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteochondroma (HP:0030431). HP:0030431 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Several affected individuals had a single osteochondroma of the femur, the tibia, or a phalanx"
Records the lesion and its sites; no denominator is given, so no frequency band.
Tall Vertebral Bodies Increased vertebral height HP:0004570 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased vertebral height (HP:0004570). HP:0004570 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Radiographic findings included tall vertebral bodies with irregular borders"
Direct radiographic description of the vertebral phenotype.
Wide Femoral Metaphysis HP:0006417 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Wide femoral metaphysis (HP:0006417). HP:0006417 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"broad femoral metaphyses with long tubular shafts"
Direct radiographic description of the metaphyseal phenotype.
Loss of Ambulation Inability to walk HP:0002540 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Inability to walk (HP:0002540). HP:0002540 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24864036 SUPPORT Human Clinical
"severe skeletal abnormalities leading to inability to walk"
Records loss of ambulation in the homozygous brothers.
Peg-Shaped Incisors Conical incisor HP:0011065 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Conical incisor (HP:0011065). HP:0011065 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37990933 SUPPORT Human Clinical
"Interestingly, peg-shaped incisors were observed in the proband, a feature never reported in CATSHL but typical of another FGFR3-related condition, LADD (Lacrimo - Auricolo - Dento - Digital) syndrome."
Records the finding and the authors' own caveat that it had never been reported in CATSHL before.
🧬

Genetic Associations

1
FGFR3
Gene: FGFR3 hgnc:3690 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FGFR3 (hgnc:3690). hgnc:3690 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"We mapped the locus causing a novel disorder characterized by camptodactyly, tall stature, scoliosis, and hearing loss (CATSHL syndrome) to chromosome 4p."
Establishes the 4p locus that contains FGFR3 and led to the gene assignment.
Variants (3)
c.1862G>A (p.Arg621His)
The founding allele, heterozygous in all 20 genotyped members of the Utah pedigree and absent from 500 ancestry-matched control chromosomes.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"we screened FGFR3 and subsequently identified a heterozygous missense mutation that is predicted to cause a p.R621H substitution in the tyrosine kinase domain and partial loss of FGFR3 function."
Names the allele and its predicted functional consequence.
c.1861C>T (p.Arg621Cys)
A second substitution at the same residue, reported in an Italian father and daughter.
Show evidence (1 reference)
PMID:37990933 SUPPORT Human Clinical
"molecular analysis revealed a hitherto unreported, monoallelic variant c.1861C>T (p.Arg621Cys) in FGFR3."
Names the second dominant allele at Arg621.
c.1637C>A (p.Thr546Lys)
A homozygous allele in two brothers of consanguineous parents, producing a more severe phenotype than either heterozygous Arg621 allele.
Show evidence (1 reference)
PMID:24864036 SUPPORT Human Clinical
"Whole exome sequencing revealed a homozygous novel missense mutation in the FGFR3 gene in exon 12 (NM_000142.4:c.1637C>A: p.(Thr546Lys))."
Names the biallelic allele with its transcript-level description.
💊

Medical Actions

4
Hearing Amplification
Action: rehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Hearing aids for the sensorineural loss. No CATSHL-specific audiological outcome data exist; this is standard care for progressive sensorineural hearing loss of any cause.
Mechanism Target:
Failure of Cochlear Pillar Cell Differentiation — Amplification compensates for the cochlear lesion; it does not act on the mechanism.
Scoliosis Surgery
Action: orthopedic surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is orthopedic surgical procedure (NCIT:C16186). NCIT:C16186 is a clinical intervention from the NCI Thesaurus. Ontology label: Orthopedic Surgical Procedure NCIT:C16186
Surgical correction for severe thoracolumbar kyphoscoliosis, one member of the Utah pedigree having roughly 80 degrees of lumbar curvature.
Mechanism Target:
Endochondral Bone and Vertebral Overgrowth — Addresses the spinal deformity that follows from vertebral overgrowth.
Physical Therapy
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Splinting and physiotherapy for digital contractures and, in the severe biallelic form, for the lower-limb deformity that costs ambulation.
Genetic Counseling
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counseling has to cover both inheritance modes, since the recurrence risk differs by a factor of two between the dominant Arg621 alleles and the recessive Thr546Lys allele.
🔬

Diagnosis

2
FGFR3 sequencing
Sequencing of the FGFR3 tyrosine kinase domain is the confirmatory test; all three published families were resolved this way, two by targeted sequencing after linkage and one by exome sequencing.
Show evidence (1 reference)
PMID:24864036 SUPPORT Human Clinical
"Whole exome sequencing revealed a homozygous novel missense mutation in the FGFR3 gene in exon 12"
Documents molecular confirmation as the diagnostic route.
Audiometry with otoacoustic emissions
Pure-tone audiometry with otoacoustic emission testing characterises the sensorineural loss; emissions are absent, consistent with an organ of Corti lesion.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"On audiological exam, each tested individual had bilateral sensorineural hearing loss and absent otoacoustic emissions"
Describes the audiological findings that define the test result.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Three families have been reported: the Utah pedigree (35 affected across seven generations, 27 living and 20 genotyped), two Egyptian brothers, and an Italian father and daughter. No population-based prevalence estimate exists, and none should be inferred from a case count - the count reflects ascertainment of individual pedigrees, not disease frequency.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"We evaluated a large Utah pedigree in which 27 living affected family members spanning four generations"
Gives the size of the founding pedigree, which is the bulk of the reported case count.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from CATSHL Syndrome:

Marfan syndrome MONDO:0007947
Overlapping Features The obvious alternative for tall stature with arachnodactyly and scoliosis, and the one the original investigators formally excluded.
Distinguishing Features
  • Severe myopia, lens dislocation and aortic root dilatation are absent in CATSHL.
  • Sensorineural hearing loss is not a feature of Marfan syndrome.
Show evidence (1 reference)
PMID:17033969 SUPPORT Human Clinical
"Marfan syndrome was considered a possible diagnosis, but no affected individuals who were examined had severe myopia, lens dislocation, or aortic-root abnormalities."
Records the exclusion and the features used to make it.
Hunter-MacDonald syndrome
Overlapping Features Shares camptodactyly, scoliosis and reduced hearing acuity, so it overlaps CATSHL on three of its four named features. Stature is the discriminator and it runs the opposite way.
Distinguishing Features
  • Short stature rather than tall stature.
  • Epiphyseal dysplasia with early osteoarthritis, and a predisposition to meningioma.
Show evidence (1 reference)
PMID:17972300 SUPPORT Human Clinical
"The skeletal manifestations of HMS include short stature, scoliosis, epiphyseal dysplasia with early osteoarthritis leading to joint replacement, prominent humeral insertions for the deltoids, camptodactyly, subluxation of the thumbs, and malformed feet."
Lists the overlapping features together with the short stature that separates it from CATSHL.
LADD syndrome
Overlapping Features Another FGFR3-related condition. Relevant because peg-shaped incisors, a LADD feature, turned up in one CATSHL proband, so the dental finding does not separate the two as cleanly as it appears to.
Distinguishing Features
  • Lacrimal, auricular and digital anomalies are the defining LADD features and are not part of CATSHL.
Show evidence (1 reference)
PMID:37990933 SUPPORT Human Clinical
"The FGFR3 p.Arg621Cys variant seems to be a newly identified cause of CATSHL syndrome with some phenotypic overlap with the LADD syndrome."
States the overlap the authors themselves drew between the two FGFR3 conditions.
🐁

Animal Models

4
Fgfr3-null mouse
The model that named the mechanism. Its phenotype was published a decade before the first human family, and the human gene was found precisely because the pedigree recapitulated the mouse.
Species
Mouse
Genotype
Fgfr3 homozygous targeted disruption
Publication
PMID:8630492
Pathograph links
Endochondral Bone and Vertebral Overgrowth recapitulates fidelity: high Skeletal overgrowth of long bones and vertebrae with kyphosis and scoliosis, matching the human radiographic pattern.
Limitations: The mouse is a complete null while the common human genotype is a heterozygous missense allele on a wild-type background, so the mouse represents a more severe loss of receptor function than the dominant human disease.
Readouts
Long bone and vertebral length
Direction: INCREASED
Interpretation: Structural correlate of the overgrowth node.
Show evidence (1 reference)
PMID:8630492 SUPPORT Model Organism
"Skeletal defects include kyphosis, scoliosis, crooked tails and curvature and overgrowth of long bones and vertebrae."
Reports the skeletal measurements behind this readout.
Show evidence (1 reference)
PMID:8630492 SUPPORT Model Organism
"Our results demonstrate that Fgfr3 is essential for normal endochondral ossification and inner ear development."
Supports treating the null mouse as informative for the endochondral overgrowth node.
Failure of Cochlear Pillar Cell Differentiation recapitulates fidelity: high Pillar cells fail to differentiate and the tunnel of Corti does not form, producing profound deafness - the cellular lesion the human sensorineural hearing loss is attributed to.
Limitations: The mouse deafness is static while the human hearing loss is progressive. The original authors read that difference as evidence that residual wild-type FGFR3 in heterozygotes delays rather than prevents the defect, and as a hint that pillar cells need FGFR3 for maintenance as well as formation - neither of which the null mouse can test.
Readouts
Pillar cell differentiation and tunnel of Corti formation
Direction: ABOLISHED
Interpretation: Histological correlate of the cochlear node.
Show evidence (1 reference)
PMID:8630492 SUPPORT Model Organism
"Inner ear defects include failure of pillar cell differentiation and tunnel of Corti formation and result in profound deafness."
Reports the cochlear histology and the resulting deafness.
Show evidence (1 reference)
PMID:8630492 SUPPORT Model Organism
"Fibroblast growth factor receptor 3 (Fgfr3) is a tyrosine kinase receptor expressed in developing bone, cochlea, brain and spinal cord."
Establishes cochlear expression, which is why the null mouse is informative for this node.
Chondrocyte-specific postnatal Fgfr3 knockout mouse
A conditional model that isolates the cartilage compartment and shows what the loss does after birth rather than during development.
Species
Mouse
Genotype
Postnatal chondrocyte-specific Fgfr3 conditional deletion
Publication
PMID:26091072
Pathograph links
Chondroma-like Lesion Formation recapitulates fidelity: moderate Multiple enchondroma- and osteochondroma-like lesions adjacent to disordered growth plates, with reduced ERK and raised IHH, and fewer lesions when hedgehog signaling is blocked.
Limitations: The mouse lesions are multiple and the human lesions solitary, and no CATSHL patient lesion has been examined for ERK or hedgehog activity, so the shared mechanism is inferred from the shared genotype rather than measured in humans.
Readouts
Chondroma-like lesion count
Direction: INCREASED
Interpretation: The lesion burden that hedgehog inhibition reduces.
Show evidence (1 reference)
PMID:26091072 SUPPORT Model Organism
"Importantly, treatment with an inhibitor of IHH signaling reduced the occurrence of chondroma-like lesions in Fgfr3-deficient mice."
Reports the lesion count responding to pathway inhibition.
Show evidence (1 reference)
PMID:26091072 SUPPORT Model Organism
"This is the first study reporting that the loss of Fgfr3 function leads to the formation of chondroma-like lesions via downregulation of MEK/ERK signaling and upregulation of IHH, suggesting that FGFR3 has a tumor suppressor-like function in chondrogenesis."
Supports treating this model as informative for the lesion node and names the proposed mechanism.
Derepressed Indian Hedgehog Signaling measures fidelity: moderate The model is where the raised IHH and lowered ERK were actually measured.
Limitations: Measured in mouse cartilage only; the equivalent measurement has never been made in human CATSHL tissue.
Readouts
Indian hedgehog expression in growth plate cartilage
Direction: INCREASED
Interpretation: The molecular readout defining this node.
Show evidence (1 reference)
PMID:26091072 SUPPORT Model Organism
"The lesions showed decreased extracellular signal-regulated kinase (ERK) activity and increased Indian hedgehog (IHH) expression."
The direct measurement of both pathway changes.
fgfr3 knockout zebrafish
Built explicitly as a CATSHL model, and the only model that reproduces the craniofacial and microcephaly features the mouse does not.
Species
Zebrafish
Genotype
CRISPR/Cas9 fgfr3 frameshift, homozygous
Publication
PMID:32641982
Pathograph links
Derepressed Indian Hedgehog Signaling recapitulates fidelity: moderate Confirms raised IHH in a second species and adds canonical Wnt/beta-catenin as a parallel derepressed pathway, with partial phenotypic rescue by a Wnt inhibitor.
Limitations: Zebrafish skeletal architecture and auditory end organs differ substantially from human, and the rescue was partial. The Wnt arm has not been examined in any mammalian Fgfr3 model, so it is currently a single-species result.
Readouts
IHH and canonical Wnt/beta-catenin pathway activity
Direction: INCREASED
Interpretation: Cross-species confirmation of the derepression node.
Show evidence (1 reference)
PMID:32641982 SUPPORT Model Organism
"we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up-regulated canonical Wnt/β-catenin signaling, and pharmacological inhibition of Wnt/β-catenin could partially alleviate the phenotypes of fgfr3 mutants."
Reports both pathway measurements and the rescue.
Show evidence (1 reference)
PMID:32641982 SUPPORT Model Organism
"We found that fgfr3 mutant zebrafish, staring from early development stage, showed craniofacial bone malformation with microcephaly and delayed closure of cranial sutures, chondroma-like lesion and abnormal development of auditory sensory organs, partially resembling the clinical manifestations..."
The authors' own statement that the model partially resembles the human disease, which is what justifies using it here.
Spider lamb syndrome sheep
Ovine hereditary chondrodysplasia, a naturally occurring sheep disease rather than an engineered model. It is the only spontaneous animal counterpart of CATSHL known, and it arose from a different FGFR3 kinase-domain substitution reached independently of the human alleles.
Species
Sheep
Genotype
Fgfr3 p.Val700Glu, naturally occurring
Publication
PMID:17033969
Pathograph links
Endochondral Bone and Vertebral Overgrowth partially recapitulates fidelity: moderate Heterozygous animals have modestly increased long-bone length; homozygotes have elongated limbs, spinal deformity and limb flexion contractures.
Limitations: The evidence here is a secondary description in the human report rather than the primary sheep literature, and no cochlear phenotype is described, so the hearing arm of the syndrome is untested in this species.
Show evidence (2 references)
PMID:17033969 SUPPORT Model Organism
"SLS is a codominant condition characterized by modestly increased long-bone length in heterozygotes"
Describes the heterozygous skeletal phenotype in sheep.
+ 1 more reference
{ }

Source YAML

click to show 
name: CATSHL Syndrome
category: Mendelian
creation_date: "2026-08-29T19:15:00Z"
synonyms:
- camptodactyly-tall stature-scoliosis-hearing loss syndrome
- camptodactyly, tall stature, and hearing loss syndrome
- CATSHLS
description: >-
  CATSHL syndrome is an ultra-rare skeletal dysplasia caused by germline loss of
  FGFR3 function. FGFR3 normally restrains chondrocyte proliferation and
  hypertrophy in the growth plate, so losing that restraint produces the mirror
  image of the FGFR3 gain-of-function chondrodysplasias: tall stature and
  overgrown long bones and vertebrae rather than short-limbed dwarfism. The
  named features are camptodactyly, tall stature, scoliosis and congenital or
  early-onset sensorineural hearing loss; developmental delay, microcephaly,
  pectus deformity and solitary osteochondromas occur in a subset. The hearing
  loss is not a secondary consequence of the skeletal disease but a separate
  requirement for FGFR3 in the cochlea, where it is needed for pillar cells of
  the organ of Corti to differentiate. Fewer than about 35 individuals have been
  reported, in three families.
disease_term:
  preferred_term: CATSHL syndrome
  term:
    id: MONDO:0012504
    label: camptodactyly-tall stature-scoliosis-hearing loss syndrome
parents:
- FGFR3-related skeletal dysplasia
classifications:
  isds_skeletal_category:
  - classification_value: fgfr3_chondrodysplasia
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, group 1
      "FGFR3 chondrodysplasia group"; CATSHL is the loss-of-function member of
      the group, which the Nosology lists alongside the gain-of-function
      disorders.
inheritance:
- name: Autosomal dominant
  description: >-
    The two heterozygous alleles reported to date, p.Arg621His and p.Arg621Cys,
    both segregate as autosomal dominant traits - across four generations of a
    Utah pedigree and between a father and his daughter in an Italian family.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we screened FGFR3 and subsequently identified a heterozygous missense mutation that is predicted to cause a p.R621H substitution in the tyrosine kinase domain and partial loss of FGFR3 function."
    explanation: A heterozygous allele segregating through a multigeneration pedigree establishes dominant transmission.
- name: Autosomal recessive
  description: >-
    One consanguineous Egyptian family carries a different allele, p.Thr546Lys,
    in the homozygous state, with unaffected heterozygous relatives. So CATSHL is
    not a single inheritance mode: the two reported Arg621 substitutions act
    dominantly, and this one does not act at all in the heterozygous state.
    Whether that difference is a property of the residue or of the substitution
    has not been tested.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:24864036
    reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report the phenotype and underlying molecular abnormality in two brothers, born to first cousin parents."
    explanation: Affected sibs of consanguineous parents carrying the variant homozygously indicate recessive inheritance for this allele.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Three families have been reported: the Utah pedigree (35 affected across
    seven generations, 27 living and 20 genotyped), two Egyptian brothers, and
    an Italian father and daughter. No population-based prevalence estimate
    exists, and none should be inferred from a case count - the count reflects
    ascertainment of individual pedigrees, not disease frequency.
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We evaluated a large Utah pedigree in which 27 living affected family members spanning four generations"
    explanation: Gives the size of the founding pedigree, which is the bulk of the reported case count.
pathophysiology:
- name: FGFR3 Kinase-Domain Loss of Function
  biological_scale: MOLECULAR
  role: trigger
  mechanism_confidence: ESTABLISHED
  description: >-
    A germline missense substitution in the FGFR3 tyrosine kinase domain reduces
    receptor kinase activity. The recurrent dominant allele replaces Arg621 in
    the catalytic loop, the residue that positions the transferred phosphate and
    is invariant across the tyrosine kinase superfamily; the recessive allele
    replaces Thr546 elsewhere in the same domain. The dominant alleles are
    unlikely to act by haploinsufficiency - the original authors give three
    reasons, of which the strongest is that heterozygous Fgfr3-null mice are
    normal - and a dominant-negative heterodimer with the wild-type receptor is
    the proposed alternative. That proposal has not been tested biochemically in
    a CATSHL allele, so the entry treats the direction of effect as established
    and the dominant-negative mechanism as the working model rather than a
    finding.
  gene:
    preferred_term: FGFR3
    description: >-
      Fibroblast growth factor receptor 3, carrying a kinase-domain missense
      variant that reduces receptor activity.
    modifier: LOSS_OF_FUNCTION
    term:
      id: hgnc:3690
      label: FGFR3
  molecular_functions:
  - preferred_term: fibroblast growth factor receptor activity
    term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    modifier: DECREASED
  genetic_context:
    gene:
      preferred_term: FGFR3
      term:
        id: hgnc:3690
        label: FGFR3
    allele_type: MISSENSE
    variant_origin: GERMLINE
    functional_impact_category: PARTIAL_LOSS_OF_FUNCTION
    zygosity: HETEROZYGOUS
    notes: >-
      Describes the two dominant Arg621 alleles, which is the common genotype.
      PARTIAL_LOSS_OF_FUNCTION rather than LOSS_OF_FUNCTION because the founding
      report describes the substitution as causing partial loss of FGFR3
      function, and DOMINANT_NEGATIVE is deliberately not used even though it is
      the proposed mechanism - it has never been demonstrated, which is what the
      catshl_dominant_negative_untested discussion is about. The p.Thr546Lys
      allele is homozygous and is not covered by this block; its zygosity is
      recorded on the variant and in the inheritance section.
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "R621 is located in the catalytic loop of the tyrosine kinase domain of FGFR3, and it is invariant in the tyrosine kinase superfamily"
    explanation: Locates the recurrent dominant substitution in the catalytic machinery of the kinase, which is why it reduces activity.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "These observations suggest that p.R621H might, instead, cause loss of FGFR3 function by a dominant negative mechanism."
    explanation: >-
      The authors' own proposal for how a heterozygous allele produces loss of
      function. Graded INDIRECT because the sentence is an inference from the
      arguments against haploinsufficiency, not a demonstration of heterodimer
      inhibition.
  - reference: PMID:24864036
    reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "This is the first report of a homozygous loss-of-function mutation in FGFR3 in human that results in a skeletal overgrowth syndrome."
    explanation: Independent confirmation that FGFR3 loss of function, not gain, produces the overgrowth phenotype.
  downstream:
  - target: Reduced MAPK/ERK Output in Growth Plate Chondrocytes
    causal_link_type: DIRECT
    description: >-
      Reduced receptor kinase activity lowers the inhibitory signal FGFR3
      normally sends into the growth plate.
  - target: Failure of Cochlear Pillar Cell Differentiation
    causal_link_type: DIRECT
    description: >-
      The same receptor is required in cochlear supporting cells, so the cochlear
      arm branches at the receptor rather than downstream of the skeletal
      pathway.

- name: Reduced MAPK/ERK Output in Growth Plate Chondrocytes
  biological_scale: MOLECULAR
  role: central_effector
  mechanism_confidence: ESTABLISHED
  description: >-
    In the proliferative and prehypertrophic growth plate, ligand-activated
    FGFR3 signals through MAPK/ERK to inhibit chondrocyte proliferation and
    hypertrophic differentiation. This is the step that makes FGFR3 a negative
    regulator of bone growth, and it is what a loss-of-function allele removes.
    The direction is the point: every other FGFR3 skeletal disorder in this
    knowledge base sits at the opposite end of the same axis.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: fibroblast growth factor receptor signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: DECREASED
  - preferred_term: ERK1 and ERK2 cascade
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
    modifier: DECREASED
  evidence:
  - reference: PMID:8601314
    reference_title: "Fibroblast growth factor receptor 3 is a negative regulator of bone growth."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis."
    explanation: States the negative-regulator role whose removal is this node.
  - reference: PMID:26091072
    reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "The lesions showed decreased extracellular signal-regulated kinase (ERK) activity and increased Indian hedgehog (IHH) expression."
    explanation: Measures the fall in ERK activity in cartilage lacking Fgfr3, which is the specific effector claim of this node.
  downstream:
  - target: Disinhibited Chondrocyte Proliferation and Hypertrophy
    causal_link_type: DIRECT
  - target: Derepressed Indian Hedgehog Signaling
    causal_link_type: DIRECT
    description: >-
      MEK inhibition alone raises Ihh expression in Fgfr3-deficient chondrocytes,
      placing the hedgehog arm downstream of the drop in MAPK output.

- name: Derepressed Indian Hedgehog Signaling
  biological_scale: MOLECULAR
  role: central_effector
  mechanism_confidence: PROVISIONAL
  description: >-
    Loss of FGFR3 raises Indian hedgehog expression in growth-plate cartilage,
    and inhibiting hedgehog signaling reduces the resulting lesions. The
    confidence is PROVISIONAL rather than established because the whole of this
    arm rests on mouse and zebrafish work; no CATSHL patient tissue has been
    examined for hedgehog pathway activity, and the human disease has not been
    shown to run through this step.
  biological_processes:
  - preferred_term: smoothened signaling pathway
    term:
      id: GO:0007224
      label: smoothened signaling pathway
    modifier: INCREASED
  evidence:
  - reference: PMID:26091072
    reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "Importantly, treatment with an inhibitor of IHH signaling reduced the occurrence of chondroma-like lesions in Fgfr3-deficient mice."
    explanation: >-
      A rescue experiment, which is stronger than the correlation - blocking the
      pathway reduces the phenotype it is proposed to cause.
  - reference: PMID:32641982
    reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up-regulated canonical Wnt/β-catenin signaling, and pharmacological inhibition of Wnt/β-catenin could partially alleviate the phenotypes of fgfr3 mutants."
    explanation: >-
      A second species reaching the same hedgehog result, and adding canonical
      Wnt as a parallel derepressed pathway.
  downstream:
  - target: Chondroma-like Lesion Formation
    causal_link_type: DIRECT

- name: Disinhibited Chondrocyte Proliferation and Hypertrophy
  biological_scale: CELLULAR
  role: central_effector
  mechanism_confidence: ESTABLISHED
  description: >-
    Without the FGFR3 brake, the proliferative and hypertrophic zones of the
    growth plate expand and chondrocytes continue to divide and enlarge for
    longer than they should. This is the cellular event that converts a receptor
    defect into extra bone length.
  cell_types:
  - preferred_term: Proliferating growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  - preferred_term: Hypertrophic chondrocyte
    term:
      id: CL:0000743
      label: hypertrophic chondrocyte
  biological_processes:
  - preferred_term: growth plate cartilage chondrocyte proliferation
    term:
      id: GO:0003419
      label: growth plate cartilage chondrocyte proliferation
    modifier: INCREASED
  evidence:
  - reference: PMID:8601314
    reference_title: "Fibroblast growth factor receptor 3 is a negative regulator of bone growth."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate."
    explanation: Directly reports the cellular expansion this node asserts.
  downstream:
  - target: Endochondral Bone and Vertebral Overgrowth
    causal_link_type: DIRECT

- name: Endochondral Bone and Vertebral Overgrowth
  biological_scale: TISSUE
  role: consequence
  mechanism_confidence: ESTABLISHED
  description: >-
    Extra growth-plate output lengthens the long bones and the vertebral bodies.
    Only bones formed by endochondral ossification are affected, which is why the
    radiographic signature is tall vertebral bodies and long tubular shafts
    rather than a generalized bone abnormality. Overlong vertebral bodies are
    also the mechanical origin of the scoliosis, so the spinal deformity is a
    consequence of the overgrowth rather than an independent feature.
  locations:
  - preferred_term: growth plate cartilage
    term:
      id: UBERON:0004129
      label: growth plate cartilage
  biological_processes:
  - preferred_term: endochondral bone growth
    term:
      id: GO:0003416
      label: endochondral bone growth
    modifier: INCREASED
  evidence:
  - reference: PMID:8601314
    reference_title: "Fibroblast growth factor receptor 3 is a negative regulator of bone growth."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth."
    explanation: Establishes enhanced and prolonged endochondral growth as the tissue-level result of losing the receptor.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts"
    explanation: The human radiographic counterpart of the mouse overgrowth phenotype.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "These findings indicate that abnormal FGFR3 signaling can cause human anomalies by promoting as well as inhibiting endochondral bone growth."
    explanation: States the bidirectional axis that makes this entry the counterpart of the achondroplasia group.

- name: Chondroma-like Lesion Formation
  biological_scale: TISSUE
  role: consequence
  mechanism_confidence: PROVISIONAL
  description: >-
    Disordered growth plates lacking FGFR3 generate enchondroma- and
    osteochondroma-like cartilage lesions in mice. Several members of the Utah
    pedigree had a solitary osteochondroma of the femur, tibia or a phalanx,
    which is the human observation this node is anchored to. The link between the
    two is not established: the human lesions are solitary and were not examined
    for hedgehog activity, while the mouse lesions are multiple and mechanistically
    dissected, so the node records a plausible correspondence rather than a
    demonstrated one.
  evidence:
  - reference: PMID:26091072
    reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "we found that postnatal chondrocyte-specific Fgfr3 deletion induced multiple chondroma-like lesions, including enchondromas and osteochondromas, adjacent to disordered growth plates."
    explanation: The model-system observation of cartilage lesions arising from Fgfr3 loss.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Several affected individuals had a single osteochondroma of the femur, the tibia, or a phalanx"
    explanation: >-
      The human counterpart. Graded INDIRECT because the report records the
      lesions without linking them to FGFR3 signaling in those individuals.

- name: Failure of Cochlear Pillar Cell Differentiation
  biological_scale: TISSUE
  role: consequence
  mechanism_confidence: ESTABLISHED
  description: >-
    FGFR3 is expressed in the cochlear supporting cells that become pillar cells,
    and losing it prevents pillar cell differentiation and tunnel of Corti
    formation, producing sensorineural deafness with a structurally normal middle
    and inner ear on imaging. This explains an otherwise puzzling feature of the
    clinical picture: the hearing loss is sensorineural and profound while CT and
    MRI are normal, because the defect is at the level of cell identity within the
    organ of Corti rather than of gross morphogenesis.
  locations:
  - preferred_term: organ of Corti
    term:
      id: UBERON:0002227
      label: spiral organ of cochlea
  cell_types:
  - preferred_term: Cochlear pillar cell
    term:
      id: CL:1000191
      label: pillar cell
  biological_processes:
  - preferred_term: inner ear morphogenesis
    term:
      id: GO:0042472
      label: inner ear morphogenesis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:8630492
    reference_title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: "Inner ear defects include failure of pillar cell differentiation and tunnel of Corti formation and result in profound deafness."
    explanation: The cellular lesion behind the hearing loss, demonstrated in the null mouse.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: "Computed tomography and magnetic resonance imaging revealed that the brain, middle ear, and inner ear were structurally normal."
    explanation: >-
      Normal imaging alongside sensorineural loss is consistent with a
      cellular-differentiation defect rather than a structural malformation.
      Graded INDIRECT because normal imaging excludes alternatives rather than
      demonstrating the pillar cell defect in patients.
phenotypes:
- category: Growth
  name: Tall Stature
  description: >-
    Postnatal overgrowth is the cardinal and most consistent feature. In the Utah
    pedigree every measured adult exceeded the 75th centile and nearly all
    exceeded the 97th.
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Adult height in males was >97th percentile in 5 of 5 men, with a mean height of 77 inches, and adult height in females was >75th percentile in 9 of 9 and >97th percentile in 8 of 9 women, with a mean height of 70 inches."
    explanation: Gives per-sex counts above the 97th and 75th centiles, supporting a VERY_FREQUENT band.
- category: Musculoskeletal
  name: Camptodactyly
  description: >-
    Fixed flexion contracture of the digits. Bound to the pooled term because the
    published count is of hands and/or feet together, so a finger-specific term
    would carry a denominator that is not finger-specific.
  phenotype_term:
    preferred_term: Camptodactyly
    term:
      id: HP:0012385
      label: Camptodactyly
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was present in 18 (90%) of 20 individuals, and 17 (85%) of 20 had hearing loss"
    explanation: 90% of genotyped individuals had camptodactyly, supporting VERY_FREQUENT.
- category: Musculoskeletal
  name: Camptodactyly of Toe
  description: >-
    The same digital contracture in the feet; the original series counted hand
    and/or foot involvement together rather than separately.
  phenotype_term:
    preferred_term: Camptodactyly of toe
    term:
      id: HP:0001836
      label: Camptodactyly of toe
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Camptodactyly of the hands and/or feet"
    explanation: >-
      Records foot involvement. No frequency is given because the published count
      pools hands and feet, so no toe-specific denominator exists.
- category: Auditory
  name: Sensorineural Hearing Loss
  description: >-
    Bilateral sensorineural hearing loss with absent otoacoustic emissions,
    congenital or beginning in early infancy, mild to severe, and variably
    progressive in early childhood.
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On audiological exam, each tested individual had bilateral sensorineural hearing loss and absent otoacoustic emissions"
    explanation: Establishes the sensorineural character and the absent otoacoustic emissions.
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By report, the hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and ranged from mild to severe."
    explanation: Supports both the congenital/early onset and the progressive course recorded in the qualifier.
- category: Musculoskeletal
  name: Scoliosis
  description: >-
    Spinal curvature, in some individuals reaching severe thoracolumbar
    kyphoscoliosis. Mechanistically this follows from the overlong vertebral
    bodies rather than being an independent malformation.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pectus abnormalities; and/or severe thoracolumbar kyphoscoliosis"
    explanation: Records the severe end of the spinal phenotype.
  review_notes: >-
    Bound to HP:0002650 Scoliosis rather than HP:0002751 Kyphoscoliosis to match
    the node name and the general finding; the source's "severe thoracolumbar
    kyphoscoliosis" describes the severe end rather than every affected
    individual. No frequency band: the source says several individuals were
    affected and then states the frequency "might be underestimated because many
    family members elected not to undergo chest and/or spine examination", so no
    denominator is available and a band would be a guess.
- category: Musculoskeletal
  name: Pectus Excavatum
  description: >-
    Anterior chest wall depression, reported in the Utah pedigree and listed
    among the recognised features of the syndrome.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several had scoliosis and/or a pectus excavatum"
    explanation: The primary report of the finding in the founding pedigree.
- category: Neurologic
  name: Developmental Delay and Intellectual Disability
  description: >-
    Developmental delay or intellectual disability in a majority of the Utah
    pedigree, and mild intellectual disability in the more severely affected of
    the two Egyptian brothers. How FGFR3 loss produces this is not accounted for
    by the skeletal or cochlear mechanism.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: FREQUENT
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 20 individuals, 12 (60%) had developmental delay and/or mental retardation, and several of these had microcephaly (head circumference <2nd percentile)."
    explanation: 60% of 20 genotyped individuals falls in the 30-79% FREQUENT band.
- category: Craniofacial
  name: High Palate
  description: >-
    A high-arched palate, listed among the recognised craniofacial features. One
    of the two features the mismatch discussion turns on that had no phenotype
    record until now.
  phenotype_term:
    preferred_term: High palate
    term:
      id: HP:0000218
      label: High palate
  evidence:
  - reference: PMID:32641982
    reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other clinical features of CATSHL syndrome include microcephaly, wormian skull bones, a high palate, pectus excavatum"
    explanation: >-
      The zebrafish paper's introduction enumerates the human clinical features
      drawn from the three case reports. Graded HUMAN_CLINICAL because the
      sentence describes patients, not the fish. No frequency band: the sentence
      is a feature list with no denominators.
- category: Craniofacial
  name: Wormian Bones
  description: >-
    Supernumerary sutural bones of the skull. The other craniofacial feature the
    mouse model does not reproduce.
  phenotype_term:
    preferred_term: Wormian bones
    term:
      id: HP:0002645
      label: Wormian bones
  evidence:
  - reference: PMID:32641982
    reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "microcephaly, wormian skull bones, a high palate"
    explanation: >-
      Same feature list. Graded HUMAN_CLINICAL for the same reason; no
      denominator, so no frequency band.
- category: Neurologic
  name: Microcephaly
  description: >-
    Head circumference below the 2nd centile in several individuals with
    developmental delay. Notable because it is one of the features the mouse
    model does not reproduce.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "several of these had microcephaly (head circumference <2nd percentile)"
    explanation: >-
      Documents microcephaly with its measurement threshold. No frequency band -
      "several" of the 12 delayed individuals gives no usable denominator.
- category: Musculoskeletal
  name: Osteochondroma
  description: >-
    Solitary benign cartilage-capped bone lesion of the femur, tibia or a
    phalanx.
  phenotype_term:
    preferred_term: Osteochondroma
    term:
      id: HP:0030431
      label: Osteochondroma
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several affected individuals had a single osteochondroma of the femur, the tibia, or a phalanx"
    explanation: Records the lesion and its sites; no denominator is given, so no frequency band.
- category: Skeletal
  name: Tall Vertebral Bodies
  description: >-
    Increased vertebral body height with irregular borders on radiographs - the
    axial-skeleton counterpart of the long-bone overgrowth.
  phenotype_term:
    preferred_term: Increased vertebral height
    term:
      id: HP:0004570
      label: Increased vertebral height
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiographic findings included tall vertebral bodies with irregular borders"
    explanation: Direct radiographic description of the vertebral phenotype.
- category: Skeletal
  name: Wide Femoral Metaphysis
  description: >-
    Broad femoral metaphyses with long tubular shafts.
  phenotype_term:
    preferred_term: Wide femoral metaphysis
    term:
      id: HP:0006417
      label: Wide femoral metaphysis
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "broad femoral metaphyses with long tubular shafts"
    explanation: Direct radiographic description of the metaphyseal phenotype.
- category: Musculoskeletal
  name: Arachnodactyly
  description: >-
    Long slender digits, reported in the two brothers homozygous for p.Thr546Lys.
  phenotype_term:
    preferred_term: Arachnodactyly
    term:
      id: HP:0001166
      label: Arachnodactyly
  evidence:
  - reference: PMID:24864036
    reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical picture is characterized by tall stature and severe skeletal abnormalities leading to inability to walk, with camptodactyly, arachnodactyly, and scoliosis."
    explanation: Reports arachnodactyly in the biallelic family.
- category: Musculoskeletal
  name: Loss of Ambulation
  description: >-
    Inability to walk from severe skeletal deformity, reported only in the
    biallelic family. This is the clearest evidence that the phenotype is
    dose-dependent.
  phenotype_term:
    preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: PMID:24864036
    reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe skeletal abnormalities leading to inability to walk"
    explanation: Records loss of ambulation in the homozygous brothers.
- category: Dental
  name: Peg-Shaped Incisors
  description: >-
    Conical incisors, reported in one proband and explicitly flagged by the
    authors as a feature of LADD syndrome rather than of CATSHL as previously
    described. It is a single observation in a single individual.
  phenotype_term:
    preferred_term: Conical incisor
    term:
      id: HP:0011065
      label: Conical incisor
  evidence:
  - reference: PMID:37990933
    reference_title: "CATSHL syndrome, a new family and phenotypic expansion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, peg-shaped incisors were observed in the proband, a feature never reported in CATSHL but typical of another FGFR3-related condition, LADD (Lacrimo - Auricolo - Dento - Digital) syndrome."
    explanation: >-
      Records the finding and the authors' own caveat that it had never been
      reported in CATSHL before.
genetic:
- name: FGFR3
  gene_term:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  relationship_type: CAUSATIVE
  notes: >-
    All three reported CATSHL alleles are missense substitutions in the FGFR3
    tyrosine kinase domain. Two affect Arg621 in the catalytic loop and act
    dominantly; the third affects Thr546 and has been seen only in the homozygous
    state.
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We mapped the locus causing a novel disorder characterized by camptodactyly, tall stature, scoliosis, and hearing loss (CATSHL syndrome) to chromosome 4p."
    explanation: Establishes the 4p locus that contains FGFR3 and led to the gene assignment.
  variants:
  - name: c.1862G>A (p.Arg621His)
    description: >-
      The founding allele, heterozygous in all 20 genotyped members of the Utah
      pedigree and absent from 500 ancestry-matched control chromosomes.
    evidence:
    - reference: PMID:17033969
      reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we screened FGFR3 and subsequently identified a heterozygous missense mutation that is predicted to cause a p.R621H substitution in the tyrosine kinase domain and partial loss of FGFR3 function."
      explanation: Names the allele and its predicted functional consequence.
  - name: c.1861C>T (p.Arg621Cys)
    description: >-
      A second substitution at the same residue, reported in an Italian father
      and daughter.
    evidence:
    - reference: PMID:37990933
      reference_title: "CATSHL syndrome, a new family and phenotypic expansion."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "molecular analysis revealed a hitherto unreported, monoallelic variant c.1861C>T (p.Arg621Cys) in FGFR3."
      explanation: Names the second dominant allele at Arg621.
  - name: c.1637C>A (p.Thr546Lys)
    description: >-
      A homozygous allele in two brothers of consanguineous parents, producing a
      more severe phenotype than either heterozygous Arg621 allele.
    evidence:
    - reference: PMID:24864036
      reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Whole exome sequencing revealed a homozygous novel missense mutation in the FGFR3 gene in exon 12 (NM_000142.4:c.1637C>A: p.(Thr546Lys))."
      explanation: Names the biallelic allele with its transcript-level description.
animal_models:
- name: Fgfr3-null mouse
  species: Mouse
  genotype: Fgfr3 homozygous targeted disruption
  publication: PMID:8630492
  description: >-
    The model that named the mechanism. Its phenotype was published a decade
    before the first human family, and the human gene was found precisely because
    the pedigree recapitulated the mouse.
  modeled_mechanisms:
  - target: Endochondral Bone and Vertebral Overgrowth
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Skeletal overgrowth of long bones and vertebrae with kyphosis and scoliosis,
      matching the human radiographic pattern.
    limitations: >-
      The mouse is a complete null while the common human genotype is a
      heterozygous missense allele on a wild-type background, so the mouse
      represents a more severe loss of receptor function than the dominant human
      disease.
    readouts:
    - name: Long bone and vertebral length
      target: Endochondral Bone and Vertebral Overgrowth
      direction: INCREASED
      interpretation: Structural correlate of the overgrowth node.
      evidence:
      - reference: PMID:8630492
        reference_title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Skeletal defects include kyphosis, scoliosis, crooked tails and curvature and overgrowth of long bones and vertebrae."
        explanation: Reports the skeletal measurements behind this readout.
    evidence:
    - reference: PMID:8630492
      reference_title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our results demonstrate that Fgfr3 is essential for normal endochondral ossification and inner ear development."
      explanation: Supports treating the null mouse as informative for the endochondral overgrowth node.
  - target: Failure of Cochlear Pillar Cell Differentiation
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Pillar cells fail to differentiate and the tunnel of Corti does not form,
      producing profound deafness - the cellular lesion the human sensorineural
      hearing loss is attributed to.
    limitations: >-
      The mouse deafness is static while the human hearing loss is progressive.
      The original authors read that difference as evidence that residual
      wild-type FGFR3 in heterozygotes delays rather than prevents the defect,
      and as a hint that pillar cells need FGFR3 for maintenance as well as
      formation - neither of which the null mouse can test.
    readouts:
    - name: Pillar cell differentiation and tunnel of Corti formation
      target: Failure of Cochlear Pillar Cell Differentiation
      direction: ABOLISHED
      interpretation: Histological correlate of the cochlear node.
      evidence:
      - reference: PMID:8630492
        reference_title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Inner ear defects include failure of pillar cell differentiation and tunnel of Corti formation and result in profound deafness."
        explanation: Reports the cochlear histology and the resulting deafness.
    evidence:
    - reference: PMID:8630492
      reference_title: "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Fibroblast growth factor receptor 3 (Fgfr3) is a tyrosine kinase receptor expressed in developing bone, cochlea, brain and spinal cord."
      explanation: Establishes cochlear expression, which is why the null mouse is informative for this node.
- name: Chondrocyte-specific postnatal Fgfr3 knockout mouse
  species: Mouse
  genotype: Postnatal chondrocyte-specific Fgfr3 conditional deletion
  publication: PMID:26091072
  description: >-
    A conditional model that isolates the cartilage compartment and shows what
    the loss does after birth rather than during development.
  modeled_mechanisms:
  - target: Chondroma-like Lesion Formation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Multiple enchondroma- and osteochondroma-like lesions adjacent to
      disordered growth plates, with reduced ERK and raised IHH, and fewer
      lesions when hedgehog signaling is blocked.
    limitations: >-
      The mouse lesions are multiple and the human lesions solitary, and no
      CATSHL patient lesion has been examined for ERK or hedgehog activity, so
      the shared mechanism is inferred from the shared genotype rather than
      measured in humans.
    readouts:
    - name: Chondroma-like lesion count
      target: Chondroma-like Lesion Formation
      direction: INCREASED
      interpretation: The lesion burden that hedgehog inhibition reduces.
      evidence:
      - reference: PMID:26091072
        reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Importantly, treatment with an inhibitor of IHH signaling reduced the occurrence of chondroma-like lesions in Fgfr3-deficient mice."
        explanation: Reports the lesion count responding to pathway inhibition.
    evidence:
    - reference: PMID:26091072
      reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "This is the first study reporting that the loss of Fgfr3 function leads to the formation of chondroma-like lesions via downregulation of MEK/ERK signaling and upregulation of IHH, suggesting that FGFR3 has a tumor suppressor-like function in chondrogenesis."
      explanation: Supports treating this model as informative for the lesion node and names the proposed mechanism.
  - target: Derepressed Indian Hedgehog Signaling
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      The model is where the raised IHH and lowered ERK were actually measured.
    limitations: >-
      Measured in mouse cartilage only; the equivalent measurement has never been
      made in human CATSHL tissue.
    readouts:
    - name: Indian hedgehog expression in growth plate cartilage
      target: Derepressed Indian Hedgehog Signaling
      direction: INCREASED
      interpretation: The molecular readout defining this node.
      evidence:
      - reference: PMID:26091072
        reference_title: "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The lesions showed decreased extracellular signal-regulated kinase (ERK) activity and increased Indian hedgehog (IHH) expression."
        explanation: The direct measurement of both pathway changes.
- name: fgfr3 knockout zebrafish
  species: Zebrafish
  genotype: CRISPR/Cas9 fgfr3 frameshift, homozygous
  publication: PMID:32641982
  description: >-
    Built explicitly as a CATSHL model, and the only model that reproduces the
    craniofacial and microcephaly features the mouse does not.
  modeled_mechanisms:
  - target: Derepressed Indian Hedgehog Signaling
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Confirms raised IHH in a second species and adds canonical Wnt/beta-catenin
      as a parallel derepressed pathway, with partial phenotypic rescue by a Wnt
      inhibitor.
    limitations: >-
      Zebrafish skeletal architecture and auditory end organs differ substantially
      from human, and the rescue was partial. The Wnt arm has not been examined in
      any mammalian Fgfr3 model, so it is currently a single-species result.
    readouts:
    - name: IHH and canonical Wnt/beta-catenin pathway activity
      target: Derepressed Indian Hedgehog Signaling
      direction: INCREASED
      interpretation: Cross-species confirmation of the derepression node.
      evidence:
      - reference: PMID:32641982
        reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "we revealed that deficiency of fgfr3 leads to enhanced IHH signaling and up-regulated canonical Wnt/β-catenin signaling, and pharmacological inhibition of Wnt/β-catenin could partially alleviate the phenotypes of fgfr3 mutants."
        explanation: Reports both pathway measurements and the rescue.
    evidence:
    - reference: PMID:32641982
      reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We found that fgfr3 mutant zebrafish, staring from early development stage, showed craniofacial bone malformation with microcephaly and delayed closure of cranial sutures, chondroma-like lesion and abnormal development of auditory sensory organs, partially resembling the clinical manifestations of patients with CATSHL syndrome."
      explanation: >-
        The authors' own statement that the model partially resembles the human
        disease, which is what justifies using it here.
- name: Spider lamb syndrome sheep
  species: Sheep
  genotype: Fgfr3 p.Val700Glu, naturally occurring
  publication: PMID:17033969
  description: >-
    Ovine hereditary chondrodysplasia, a naturally occurring sheep disease rather
    than an engineered model. It is the only spontaneous animal counterpart of
    CATSHL known, and it arose from a different FGFR3 kinase-domain substitution
    reached independently of the human alleles.
  modeled_mechanisms:
  - target: Endochondral Bone and Vertebral Overgrowth
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Heterozygous animals have modestly increased long-bone length; homozygotes
      have elongated limbs, spinal deformity and limb flexion contractures.
    limitations: >-
      The evidence here is a secondary description in the human report rather
      than the primary sheep literature, and no cochlear phenotype is described,
      so the hearing arm of the syndrome is untested in this species.
    evidence:
    - reference: PMID:17033969
      reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "SLS is a codominant condition characterized by modestly increased long-bone length in heterozygotes"
      explanation: Describes the heterozygous skeletal phenotype in sheep.
    - reference: PMID:17033969
      reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "SLS is caused by a substitution of glutamic acid for valine at amino acid position 700 (p.V700E) in the tyrosine kinase of Fgfr3"
      explanation: Names the ovine allele and locates it in the same kinase domain as the human alleles.
diagnosis:
- name: FGFR3 sequencing
  description: >-
    Sequencing of the FGFR3 tyrosine kinase domain is the confirmatory test; all
    three published families were resolved this way, two by targeted sequencing
    after linkage and one by exome sequencing.
  evidence:
  - reference: PMID:24864036
    reference_title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whole exome sequencing revealed a homozygous novel missense mutation in the FGFR3 gene in exon 12"
    explanation: Documents molecular confirmation as the diagnostic route.
- name: Audiometry with otoacoustic emissions
  description: >-
    Pure-tone audiometry with otoacoustic emission testing characterises the
    sensorineural loss; emissions are absent, consistent with an organ of Corti
    lesion.
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On audiological exam, each tested individual had bilateral sensorineural hearing loss and absent otoacoustic emissions"
    explanation: Describes the audiological findings that define the test result.
differential_diagnoses:
- name: Marfan syndrome
  disease_term:
    preferred_term: Marfan syndrome
    term:
      id: MONDO:0007947
      label: Marfan syndrome
  description: >-
    The obvious alternative for tall stature with arachnodactyly and scoliosis,
    and the one the original investigators formally excluded.
  distinguishing_features:
  - Severe myopia, lens dislocation and aortic root dilatation are absent in CATSHL.
  - Sensorineural hearing loss is not a feature of Marfan syndrome.
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Marfan syndrome was considered a possible diagnosis, but no affected individuals who were examined had severe myopia, lens dislocation, or aortic-root abnormalities."
    explanation: Records the exclusion and the features used to make it.
- name: Hunter-MacDonald syndrome
  description: >-
    Shares camptodactyly, scoliosis and reduced hearing acuity, so it overlaps
    CATSHL on three of its four named features. Stature is the discriminator and
    it runs the opposite way.
  distinguishing_features:
  - Short stature rather than tall stature.
  - Epiphyseal dysplasia with early osteoarthritis, and a predisposition to meningioma.
  evidence:
  - reference: PMID:17972300
    reference_title: "The Hunter-MacDonald syndrome with expanded phenotype including risk of meningioma: an update and review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The skeletal manifestations of HMS include short stature, scoliosis, epiphyseal dysplasia with early osteoarthritis leading to joint replacement, prominent humeral insertions for the deltoids, camptodactyly, subluxation of the thumbs, and malformed feet."
    explanation: Lists the overlapping features together with the short stature that separates it from CATSHL.
- name: LADD syndrome
  description: >-
    Another FGFR3-related condition. Relevant because peg-shaped incisors, a
    LADD feature, turned up in one CATSHL proband, so the dental finding does not
    separate the two as cleanly as it appears to.
  distinguishing_features:
  - Lacrimal, auricular and digital anomalies are the defining LADD features and are not part of CATSHL.
  evidence:
  - reference: PMID:37990933
    reference_title: "CATSHL syndrome, a new family and phenotypic expansion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The FGFR3 p.Arg621Cys variant seems to be a newly identified cause of CATSHL syndrome with some phenotypic overlap with the LADD syndrome."
    explanation: States the overlap the authors themselves drew between the two FGFR3 conditions.
treatments:
- name: Hearing Amplification
  description: >-
    Hearing aids for the sensorineural loss. No CATSHL-specific audiological
    outcome data exist; this is standard care for progressive sensorineural
    hearing loss of any cause.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  target_mechanisms:
  - target: Failure of Cochlear Pillar Cell Differentiation
    description: >-
      Amplification compensates for the cochlear lesion; it does not act on the
      mechanism.
- name: Scoliosis Surgery
  description: >-
    Surgical correction for severe thoracolumbar kyphoscoliosis, one member of
    the Utah pedigree having roughly 80 degrees of lumbar curvature.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Endochondral Bone and Vertebral Overgrowth
    description: >-
      Addresses the spinal deformity that follows from vertebral overgrowth.
- name: Physical Therapy
  description: >-
    Splinting and physiotherapy for digital contractures and, in the severe
    biallelic form, for the lower-limb deformity that costs ambulation.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
- name: Genetic Counseling
  description: >-
    Counseling has to cover both inheritance modes, since the recurrence risk
    differs by a factor of two between the dominant Arg621 alleles and the
    recessive Thr546Lys allele.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
discussions:
- discussion_id: catshl_craniofacial_model_mismatch
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Why do CATSHL patients have craniofacial abnormalities and microcephaly when
    Fgfr3-deficient mice have no craniofacial phenotype at all?
  rationale: >-
    The mouse reproduces the two features that made it the candidate model -
    skeletal overgrowth and deafness - and reproduces them well. It does not
    reproduce microcephaly, high palate or wormian bones, which are recorded in
    the human families. This is not a gap in evidence but a discordance between
    species: the measurement has been made in the mouse and the answer is
    negative. The zebrafish does show microcephaly and delayed suture closure,
    which makes the mouse the outlier rather than the human, but zebrafish
    craniofacial development is far enough from human that it cannot settle the
    mechanism. Until it is resolved, the craniofacial and neurodevelopmental
    features of CATSHL have no model system that both shows them and is close
    enough to human to interpret.
  attaches_to:
  - phenotypes#Microcephaly
  - phenotypes#High Palate
  - phenotypes#Wormian Bones
  - phenotypes#Developmental Delay and Intellectual Disability
  evidence:
  - reference: PMID:32641982
    reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The reason for the discrepant in the craniofacial phenotypes between mouse model and patients remains to be studied."
    explanation: >-
      The authors state the mismatch explicitly and record it as unresolved.
      Quoted as written, including the grammatical slip in the original.
  - reference: PMID:32641982
    reference_title: "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "craniofacial bone malformation with microcephaly and delayed closure of cranial sutures"
    explanation: Establishes that the zebrafish, unlike the mouse, does show the craniofacial phenotype.
- discussion_id: catshl_dominant_negative_untested
  kind: KNOWLEDGE_GAP
  prompt: >-
    Do the Arg621 alleles act as dominant negatives, and if so does the mutant
    receptor actually inhibit its wild-type partner?
  rationale: >-
    The dominant-negative model is the only explanation on offer, and the
    arguments against haploinsufficiency are good ones. But the positive claim
    has never been tested: nobody has shown that mutant FGFR3 heterodimerises
    with the wild-type receptor and suppresses its kinase activity. The evidence
    offered is that mutant and wild-type transcripts are expressed at comparable
    levels and both proteins reach the membrane, which is consistent with a
    dominant negative and equally consistent with a simple hypomorph whose
    threshold effects differ between tissues. The distinction matters for whether
    the two Arg621 substitutions and the Thr546Lys allele share one mechanism.
  attaches_to:
  - pathophysiology#FGFR3 Kinase-Domain Loss of Function
  evidence:
  - reference: PMID:17033969
    reference_title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For several reasons, it is unlikely that the loss of function caused by p.R621H results from haploinsufficiency."
    explanation: The authors' own framing of the mechanism as an inference from exclusion rather than a demonstration.
- discussion_id: catshl_bidirectional_cochlear_failure
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why does either too little or too much FGFR3 signaling cause deafness?
  rationale: >-
    Loss of Fgfr3 abolishes pillar cell differentiation; the activating Y367C
    allele produces fully penetrant deafness with an increased number of pillar
    or modified supporting cells. The organ of Corti therefore fails in both
    directions from an intermediate optimum, which is unusual and is not
    explained by a simple dose-response model of the receptor. Whether the two
    deafnesses share a final common lesion or are distinct failures of the same
    patterning step is unknown, and the answer would constrain how the human
    hearing loss is expected to progress.
  attaches_to:
  - pathophysiology#Failure of Cochlear Pillar Cell Differentiation
  evidence:
  - reference: PMID:19073250
    reference_title: "Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The inner ear defect is mainly associated with an increased number of pillar cells or modified supporting cells in the organ of Corti."
    explanation: >-
      Shows the gain-of-function receptor producing the opposite cellular change
      in the same structure, which is what makes the bidirectional failure a real
      question rather than a rhetorical one.
  - reference: PMID:19073250
    reference_title: "Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The mutant Fgfr3(Y367C/+) mice exhibit fully penetrant deafness with a significantly elevated auditory brainstem response threshold for all frequencies tested."
    explanation: Establishes that the activating allele also causes deafness, not merely a cellular change.
references:
- reference: PMID:17033969
  title: "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome."
- reference: PMID:24864036
  title: "A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly."
- reference: PMID:37990933
  title: "CATSHL syndrome, a new family and phenotypic expansion."
review_notes: >-
  Two uncited files in references_cache come from the deep-research report's own
  citation-validation pass, not from this entry:
  DOI_10.1371_journal.pgen.1005214.md, which is the same paper as the cited
  PMID:26091072 and is kept because the report cites it in DOI form, and
  DOI_10.1002_dvdy.21026.md, a Dev Dyn paper on excess hair cell development in
  Fgfr3-null mice that the report cites without an abstract in the cache, so
  nothing in it was quotable. Every other cached reference in this PR is cited.
notes: >-
  Scope and modelling decisions recorded so they do not read as omissions.

  No conforms_to against fgfr_gain_of_function_skeletal_dysplasia. That module is
  explicitly genotype-driven and scoped to activating FGFR alleles - its entry
  node is a constitutively active receptor driving sustained MAPK/STAT output.
  CATSHL runs the same axis in the opposite direction, so declaring conformance
  would assert the reverse of what the module's nodes say. The two belong
  together as a contrast, not as a conformance relationship.

  No clinical_trials and no disease-modifying treatment. Nothing is registered
  for CATSHL. The FGFR3-directed therapies in development - vosoritide and the
  FGFR inhibitors - all aim to reduce FGFR3 pathway output and are therefore
  pointed the wrong way for this disease. The hedgehog and Wnt inhibitors that
  rescue the animal models have not been given to a patient.

  No environmental section. The disease is monogenic with no reported
  environmental modifier.

  The Fgfr3 Y367C mouse is deliberately not curated under animal_models. It
  carries an activating allele and models thanatophoric dysplasia, not this
  disease; it appears only as evidence in the discussion about bidirectional
  cochlear failure, which is the only claim it supports here.
📚

References & Deep Research

References

3
PMID:17033969
A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.
No top-level findings curated for this source.
PMID:24864036
A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly.
No top-level findings curated for this source.
PMID:37990933
CATSHL syndrome, a new family and phenotypic expansion.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
CATSHL Syndrome (Camptodactyly, Tall Stature, and Hearing Loss Syndrome): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 13 citations 2026-08-29T19:40:46.123339

CATSHL Syndrome (Camptodactyly, Tall Stature, and Hearing Loss Syndrome): Comprehensive Research Report

1. Disease Information

Overview. CATSHL syndrome — an acronym for CAmptodactyly, Tall Stature, and Hearing Loss — is an ultra-rare skeletal dysplasia/overgrowth syndrome caused by loss-of-function variants in the FGFR3 (fibroblast growth factor receptor 3) gene. It is notable as essentially the phenotypic mirror image of achondroplasia: whereas achondroplasia results from gain-of-function FGFR3 mutations that cause short stature, CATSHL results from loss-of-function FGFR3 mutations that cause tall stature, alongside camptodactyly, scoliosis/chest-wall anomalies, and congenital or early-onset sensorineural hearing loss Toydemir et al., 2006, Am J Hum Genet 79(5):935-941, PMID:17033969.

Key identifiers: - OMIM: #610474 (CATSHLS — CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME) — gene locus FGFR3 (134934) OMIM 610474 - Orphanet: ORPHA:85164 — "Camptodactyly-tall stature-scoliosis-hearing loss syndrome" Orphanet 85164 - MONDO: MONDO:0012504 - Disease Ontology: DOID:0111160 - MedGen/UMLS Concept: C1864852 NCBI MedGen 355844 - Gene:* FGFR3, chromosome 4p16.3; HGNC gene ID for the causal gene

Synonyms: CATSHL syndrome; Camptodactyly–tall stature–hearing loss syndrome; Camptodactyly–tall stature–scoliosis–hearing loss syndrome.

Data provenance. Nearly all published knowledge of CATSHL derives from a small number of aggregated pedigree/case reports in the peer-reviewed literature (not large-scale EHR or registry data), supplemented by animal-model studies (mouse and zebrafish Fgfr3 loss-of-function models) that established the underlying mechanism before and alongside the human descriptions.

2. Etiology

Primary cause — genetic (monogenic). CATSHL is caused by heterozygous (autosomal dominant) or, more rarely, homozygous (autosomal recessive) missense loss-of-function mutations in FGFR3, the gene encoding a receptor tyrosine kinase that normally acts as a negative regulator of bone growth in the cartilage growth plate Colvin et al., 1996, Nat Genet 12:390-397, PMID:8630492; Deng et al., 1996, Cell, PMID:8601314.

Genetic risk factors / causal variants identified to date:

Variant (protein) cDNA change Zygosity/Inheritance Family Reference
p.Arg621His (R621H) c.1862G>A Heterozygous, autosomal dominant 27 living affected of a 4-generation (7-generation historically) Utah pedigree (~35 affected total) Toydemir et al. 2006, PMID:17033969
p.Thr546Lys (T546K) c.1637C>A Homozygous, autosomal recessive (consanguineous parents); heterozygous carriers unaffected 2 brothers, consanguineous Egyptian family Makrythanasis et al. 2014, Hum Mutat 35:959-963
p.Arg621Cys (R621C) c.1861C>T Heterozygous, autosomal dominant (novel, same residue as R621H but different substitution) Father and 12-year-old daughter, Italian family (new 2024 report) Cannova et al. 2024, Clin Genet 105:313-316, PMID:37990933

All are located in/near the tyrosine kinase domain of FGFR3 and are functionally characterized as reducing (R621H, partial loss) or abolishing receptor kinase activity, in contrast to the gain-of-function substitutions (e.g., G380R, K650E) that cause achondroplasia/thanatophoric dysplasia at other FGFR3 residues.

Environmental/lifestyle risk factors: None identified — CATSHL is a purely monogenic condition; no environmental, infectious, or lifestyle contributors have been reported.

Protective factors: None specifically documented. No modifier genes or protective alleles are reported in the literature to date.

Gene-environment interaction: Not applicable/not studied — this is a fully penetrant single-gene disorder with no reported environmental modulation.

3. Phenotypes

Core tetrad

  1. Camptodactyly — permanent, irreducible flexion of one or more fingers and/or toes (HPO: HP:0012385, Camptodactyly, or the more general HP:0002813, Abnormality of joint mobility)
  2. Tall stature — postnatal-onset overgrowth, disproportionate to family background (HPO: HP:0000098, Tall stature)
  3. Scoliosis / chest-wall anomalies — scoliosis and/or pectus excavatum (HPO: HP:0002650 Scoliosis; HP:0000767 Pectus excavatum)
  4. Sensorineural hearing loss — bilateral, with absent otoacoustic emissions, congenital or early-infancy onset, variably progressive, ranging mild–severe (HPO: HP:0000407, Sensorineural hearing impairment; HP:0008625, Bilateral sensorineural hearing impairment)

Additional reported phenotypes

  • Microcephaly in a subset of patients (HPO: HP:0000252)
  • Developmental delay / intellectual disability — reported in some patients, notably the more severely affected Egyptian brother (IQ ~70) in the homozygous T546K family (HPO: HP:0001263 Developmental delay; HP:0001249 Intellectual disability)
  • Severe lateral tibial deviation, arachnodactyly, and inability to ambulate in the severe homozygous (recessive) presentation (Makrythanasis et al. 2014)
  • Peg-shaped incisors — newly described in the 2024 Italian family with p.Arg621Cys, a feature overlapping with LADD (Lacrimo-Auriculo-Dento-Digital) syndrome, another FGFR3-spectrum condition — representing a phenotypic expansion of CATSHL Cannova et al. 2024, PMID:37990933
  • Lower-limb joint abnormalities

Phenotype characteristics

  • Onset: Tall stature typically becomes apparent postnatally/in childhood; hearing loss is congenital or manifests in early infancy; camptodactyly is present from early life.
  • Severity/course: Hearing loss is variably progressive in early childhood; overall severity is markedly worse in the homozygous/biallelic (recessive) form (inability to walk, more pronounced skeletal deformity, intellectual disability) than in the heterozygous dominant form.
  • Frequency among affected individuals: Camptodactyly, tall stature, and hearing loss are present in essentially all reported/genetically confirmed cases (definitional); scoliosis/pectus excavatum, microcephaly, and intellectual disability are variable/less penetrant secondary features.
  • Quality of life impact: Not formally studied with standardized instruments (no EQ-5D/SF-36 data identified); clinically, hearing loss and orthopedic/mobility impairment (particularly in the recessive form) are the primary functional burdens.

4. Genetic/Molecular Information

  • Causal gene: FGFR3 (Fibroblast Growth Factor Receptor 3), HGNC gene, OMIM 134934, chromosome 4p16.3*.
  • Variant classification: All reported CATSHL variants are missense, classified as pathogenic/likely pathogenic loss-of-function or partial-loss-of-function alleles (ACMG/AMP framework); ClinVar entries exist for c.1637C>A (p.Thr546Lys) ClinVar RCV000144699 and for the R621H/R621C tyrosine-kinase-domain substitutions.
  • Variant type: All missense substitutions clustered in or near the tyrosine kinase domain — distinct from the extracellular Ig-like/transmembrane domain hotspots (e.g., G380R) that cause the gain-of-function achondroplasia spectrum.
  • Somatic vs. germline: All reported CATSHL variants are germline; no somatic CATSHL cases reported (unlike some FGFR3 gain-of-function conditions, which can also arise somatically in certain skin/bladder neoplasms — not relevant here).
  • Functional consequence: Loss of function / partial loss of function of FGFR3 kinase activity. Because FGFR3 is normally an inhibitory (negative) regulator of chondrocyte proliferation/differentiation and bone growth, its functional inactivation derepresses growth-plate chondrogenesis, producing skeletal overgrowth — the inverse of achondroplasia's growth suppression from constitutive receptor activation. The dominant R621H allele behaves as a partial loss-of-function/possible dominant-negative allele sufficient to cause disease in the heterozygous state, whereas T546K requires biallelic (homozygous) loss for full clinical expression — heterozygous T546K carriers (parents, unaffected sister) are clinically unaffected, indicating a milder functional deficit per allele than R621H.
  • Allele frequency: These are private, rare familial variants; not appreciable in population databases such as gnomAD (consistent with disease-causing rarity).
  • Modifier genes: None established; the recessive vs. dominant difference between T546K and R621H appears to reflect differing residual kinase activity of each specific substitution rather than a separate modifier locus.
  • Epigenetics/chromosomal abnormalities: None reported — CATSHL is caused by point mutations, not by copy-number, translocation, or epigenetic mechanisms.

5. Environmental Information

No environmental, infectious, occupational, or lifestyle contributing factors have been identified or hypothesized for CATSHL syndrome in the literature; it is presented uniformly as a monogenic Mendelian condition with full genetic causation.

6. Mechanism / Pathophysiology

Molecular pathway and causal chain

FGFR3 is a receptor tyrosine kinase highly expressed in the proliferative and prehypertrophic zones of the cartilage growth plate, as well as in the cochlea, brain, and spinal cord. In the growth plate, ligand-activated FGFR3 signals principally through the MAPK/ERK cascade (and secondarily PI3K/AKT, PKCγ, and STAT1) to inhibit chondrocyte proliferation and hypertrophic differentiation, thereby restraining endochondral bone elongation — i.e., FGFR3 is physiologically a negative regulator of bone growth Colvin et al. 1996, PMID:8630492; Deng et al. 1996, Cell, PMID:8601314.

  • In achondroplasia/thanatophoric dysplasia, gain-of-function FGFR3 mutations hyperactivate this inhibitory MAPK signal → excess growth suppression → short-limbed dwarfism.
  • In CATSHL, loss-of-function FGFR3 mutations reduce MAPK-mediated inhibition of chondrocyte proliferation/hypertrophy → disinhibited endochondral growth → tall stature and long-bone/vertebral overgrowth. Conditional chondrocyte-specific Fgfr3 knockout mice show markedly lengthened growth plates, increased osteoblast number, and increased bone formation and bone mass.
  • Postnatal Fgfr3 deletion in chondrocytes also produces chondroma-like lesions (enchondromas/osteochondromas) adjacent to disordered growth plates, associated with decreased ERK activity and upregulated Indian hedgehog (IHH) signaling; pharmacologic IHH-pathway inhibition reduced lesion occurrence in Fgfr3-deficient mice, implicating derepressed Hedgehog signaling as a downstream driver of the skeletal dysplasia phenotype Zhou et al. 2015, PLOS Genetics, PMID (Zhou/Wen/Chen et al.); doi:10.1371/journal.pgen.1005214.
  • A zebrafish CRISPR/Cas9 fgfr3 loss-of-function model (frameshift mutations in the tyrosine-kinase domain) recapitulated microcephaly, craniofacial dysmorphism (domed skull, mandibular deformity), delayed endochondral and intramembranous ossification, chondroma-like growth-plate lesions, and abnormal chondrocyte hypertrophy — and demonstrated enhanced canonical Wnt/β-catenin signaling alongside increased IHH signaling as a partial molecular driver; pharmacologic Wnt/β-catenin inhibition (XAV939) partially rescued the chondrocyte/craniofacial phenotype, suggesting a therapeutic pathway target Sun X. et al. 2020, Theranostics 10(16):7111-7130, PMID:32641982.

Hearing loss mechanism

FGFR3 is expressed from approximately embryonic day 16 in the mouse cochlear duct in a domain that gives rise to pillar cells, outer hair cells, and Deiters' cells, and becomes restricted to pillar cells by birth. FGF8 signals from inner hair cells to FGFR3-expressing supporting cells to drive pillar-cell differentiation. Fgfr3-null mice show failure of pillar cell differentiation and failure of tunnel-of-Corti formation, with two rows of undifferentiated cells persisting in the pillar-cell region, altered pillar-cell innervation/fiber-guidance, and profound deafness — establishing FGFR3 loss-of-function as directly causal for the inner-ear phenotype, mirroring the human sensorineural hearing loss in CATSHL Colvin et al. 1996, PMID:8630492; Puligilla et al./Mueller et al., FGFR3 pillar cell studies, J Neurosci 22(21):9368; Hayashi et al. 2007, Dev Dyn, "Loss of Fgfr3 leads to excess hair cell development in the mouse organ of Corti". Downstream transcription factors Etv4/Etv5/Etv1 appear to act as key FGFR3-dependent regulators of pillar-cell identity. This contrasts with the reciprocal FGFR3 gain-of-function mouse model (activating Y367C mutation, modeling Muenke/achondroplasia-spectrum craniosynostosis), which also causes hearing loss but via excessive FGF signaling and altered pillar/Deiters cell ratios — indicating that both too little and too much FGFR3 signaling disrupt normal organ of Corti patterning [PMID:19073250].

Causal chain summary

FGFR3 loss-of-function variant (germline) → reduced receptor tyrosine kinase activity → diminished inhibitory MAPK/ERK signaling in growth-plate chondrocytes + derepressed IHH and Wnt/β-catenin signaling → disinhibited chondrocyte proliferation/hypertrophy and endochondral ossification → long-bone/vertebral overgrowth (tall stature), joint contractures (camptodactyly), spinal curvature (scoliosis); in parallel, loss of FGFR3-dependent FGF8 signal transduction in cochlear supporting cells → failure of pillar cell differentiation/tunnel of Corti formation → sensorineural hearing loss.

Suggested ontology terms

  • GO (biological process): GO:0007173 (epidermal growth factor receptor signaling pathway analog)/more precisely GO:0008543 (fibroblast growth factor receptor signaling pathway); GO:0060445 (branching involved in salivary gland morphogenesis – not relevant); relevant terms: GO:0060563 (Deiters' cell differentiation-adjacent), GO:0003417 (growth plate cartilage chondrocyte growth), GO:0061036 (positive regulation of cartilage development), GO:0021940 (positive regulation of cerebellar granule cell precursor proliferation – not relevant); most directly: GO:0008543 (fibroblast growth factor receptor signaling pathway), GO:0061181 (regulation of chondrocyte development), MAPK cascade GO:0000165.
  • GO (molecular function): GO:0005007 (fibroblast growth factor-activated receptor activity), GO:0004713 (protein tyrosine kinase activity)
  • GO (cellular component): GO:0005886 (plasma membrane), GO:0043235 (receptor complex)
  • CL (cell types): CL:0000138 (chondrocyte), CL:0000743 (hypertrophic chondrocyte), pillar cell (organ of Corti; CL term for inner/outer pillar cell), CL:0002261 (Deiters' cell / cochlear supporting cell), CL:0000062 (osteoblast)

7. Anatomical Structures Affected

Organ level: - Skeletal system: long bones (femur, tibia), vertebral column (scoliosis), phalanges/digits (camptodactyly), thoracic cage (pectus excavatum) — primary - Inner ear/cochlea: organ of Corti — primary - CNS: brain (microcephaly in a subset) — secondary - Body systems involved: musculoskeletal, auditory, and (variably) nervous system

Tissue/cell level: - Cartilage/growth plate — chondrocytes (proliferative and hypertrophic zones) — UBERON: growth plate cartilage - Bone — osteoblasts, endochondral and intramembranous ossification centers - Organ of Corti — pillar cells, Deiters' cells, outer hair cells, inner hair cells (Cell Ontology terms as above)

Subcellular level: FGFR3 is a plasma membrane receptor tyrosine kinase (GO:0005886); downstream effectors act in the cytoplasm (MAPK/ERK cascade components) and nucleus (transcriptional targets such as Etv4/5/1, and IHH/Wnt-β-catenin pathway effectors).

Localization/laterality: Skeletal overgrowth and camptodactyly are typically bilateral (may be asymmetric in digit involvement); hearing loss is bilateral sensorineural.

Relevant UBERON terms: UBERON:0002391 (cartilage of epiphysis / growth plate — approximate), UBERON:0001690 (ear), UBERON:0004674 (organ of Corti / spiral organ), UBERON:0002228 (rib cage / thoracic skeleton), UBERON:0002101 (limb).

8. Temporal Development

  • Onset: Congenital/early-infancy onset of hearing loss; tall stature emerges as a postnatal growth pattern typically evident in childhood; camptodactyly present from early life; scoliosis often develops/becomes apparent during growth (childhood/adolescence).
  • Onset pattern: Insidious/developmental rather than acute.
  • Progression: Hearing loss is described as variably progressive in early childhood, ranging from mild to severe by later assessment; skeletal overgrowth and scoliosis progress with growth and may stabilize post-puberty (as in other overgrowth syndromes), though formal longitudinal natural-history data are not established in the literature reviewed.
  • Disease course: Chronic, lifelong; no spontaneous remission reported. No mortality has been attributed to CATSHL in the literature to date — prognosis for survival is considered favorable.
  • Severity gradient over time: The recessive (homozygous T546K) presentation is more severe and disabling from an early age (loss of ambulation) than the dominant (heterozygous R621H/R621C) presentation.

9. Inheritance and Population

  • Inheritance pattern: Predominantly autosomal dominant (heterozygous R621H, R621C); rarely autosomal recessive (homozygous T546K in a consanguineous family, with unaffected heterozygous carrier parents/sibling) [Makrythanasis et al. 2014].
  • Penetrance: Appears high/complete for the dominant form within the reported Utah pedigree (affected individuals across 4–7 generations); the recessive T546K allele is essentially non-penetrant in the heterozygous state (unaffected carrier parents and sister), consistent with a true recessive, dosage-dependent mechanism.
  • Expressivity: Variable — severity (ambulation, intellectual disability, degree of hearing loss) differs between the dominant and recessive forms and even between siblings (e.g., the two Egyptian brothers differed in severity, with the older being unable to walk and having mild intellectual disability).
  • Genetic anticipation: Not reported.
  • Germline mosaicism: Not reported in the literature reviewed.
  • Founder effects/consanguinity: The recessive T546K case arose in a consanguineous Egyptian family, illustrating the classic mechanism by which a rare recessive allele can become homozygous; no broader founder-population data.
  • Carrier frequency: Not established (each identified variant is a private/family-specific finding, not present at appreciable frequency in population databases such as gnomAD).

Population demographics/epidemiology: - Extreme rarity: As of the most recent literature reviewed, approximately 30 documented individuals worldwide — the original 27 living affected members of the 4-generation (35 total across 7-generation) Utah pedigree [Toydemir et al. 2006], 2 brothers from a consanguineous Egyptian family [Makrythanasis et al. 2014], and most recently 2 additional affected individuals (father and daughter) from an Italian family with a novel variant [Cannova et al. 2024]. No formal population prevalence or incidence estimate exists (Orphanet lists it in the "not yet documented"/single-family-reported prevalence class). - Geographic distribution: Cases reported from the United States (Utah), Egypt, and Italy — no evidence of a specific endemic region; likely reflects ascertainment of individual pedigrees rather than a true geographic pattern. - Sex ratio: No skewed sex ratio reported (autosomal inheritance; both sexes affected in all reported families). - Age distribution: All age groups from childhood through adulthood represented across the reported pedigrees, consistent with a lifelong, non-lethal condition.

10. Diagnostics

Clinical recognition: Diagnosis is suspected clinically from the combination of postnatal-onset tall stature, camptodactyly, scoliosis/pectus excavatum, and bilateral sensorineural hearing loss with absent otoacoustic emissions, particularly in the setting of a compatible family history (autosomal dominant transmission across generations, or consanguinity for the recessive form).

Confirmatory genetic testing: - Single-gene FGFR3 sequencing (Sanger or targeted next-generation sequencing) of the tyrosine kinase domain exons is the definitive diagnostic test, as performed in all published cases (identification of R621H, T546K, R621C). - Gene panels for skeletal dysplasia/overgrowth or for syndromic hearing loss that include FGFR3 would be expected to capture CATSHL variants (per commercial genetic testing registries, e.g., NIH GTR listing for "Camptodactyly-tall stature-scoliosis-hearing loss syndrome," condition C1864852) NIH GTR. - Exome sequencing was the discovery method for the recessive T546K family (Makrythanasis et al. 2014), confirmed by Sanger sequencing and segregation analysis. - Audiometry/otoacoustic emissions testing to characterize and monitor the sensorineural hearing loss. - Skeletal radiographs to assess long-bone length, vertebral alignment (scoliosis), and joint contractures.

Differential diagnosis: Other overgrowth syndromes (e.g., Marfan syndrome, Sotos syndrome, homocystinuria) and other syndromic sensorineural hearing loss conditions should be considered; the co-occurrence of tall stature with hearing loss (rather than short stature, which characterizes the far more common FGFR3 gain-of-function conditions) is the key distinguishing clue toward FGFR3 loss-of-function/CATSHL. The 2024 Italian family report also highlights phenotypic overlap with LADD syndrome (another FGFR3-related condition) via a shared dental finding (peg-shaped incisors), underscoring the importance of molecular confirmation.

Screening: No population-based or newborn screening program exists for this ultra-rare condition; diagnosis relies on clinical suspicion and targeted/family-based genetic testing.

11. Outcome/Prognosis

  • Survival/mortality: No CATSHL-attributable deaths have been reported in the literature reviewed; life expectancy appears unaffected.
  • Morbidity: Primary functional morbidity relates to (a) sensorineural hearing loss (variable severity, potentially requiring amplification) and (b) orthopedic/mobility impact of severe skeletal deformity, most pronounced in the recessive (homozygous) form, where the more severely affected sibling was unable to walk.
  • Neurodevelopmental outcome: Developmental delay/intellectual disability is reported in a subset, more prominently associated with the recessive form (IQ ~70 in the more severely affected Egyptian brother) than clearly established for the dominant form.
  • Prognostic factors: Zygosity/allele appears to be the principal prognostic determinant identified to date — biallelic (homozygous) loss-of-function produces a substantially more severe phenotype than monoallelic (heterozygous) loss-of-function, consistent with a dosage-dependent mechanism.
  • Quality of life: Not formally quantified with standardized instruments in the literature reviewed.

12. Treatment

There is no disease-modifying or curative therapy for CATSHL syndrome; management is symptomatic and supportive, informed by general principles for the component features:

  • Hearing rehabilitation: Hearing aids for mild-to-severe sensorineural hearing loss with adequate speech discrimination; cochlear implantation would be a consideration for severe/profound loss, by analogy with management of other syndromic sensorineural hearing loss conditions, though CATSHL-specific implantation outcome data were not identified in the literature reviewed. (NCIT: NCIT:C15302 general rehabilitative care; hearing-aid fitting and cochlear implantation are standard-of-care interventions for sensorineural hearing loss broadly.)
  • Orthopedic management: Monitoring and, where indicated, surgical correction of scoliosis (NCIT:C15329, Surgical Procedure / orthopedic spinal surgery) and management of joint contractures/camptodactyly (splinting, physical therapy — NCIT:C15302, Physical Therapy) and severe lower-limb deformity (as in the recessive Egyptian family, where severe tibial deviation contributed to loss of ambulation).
  • Developmental/educational support: For patients with developmental delay/intellectual disability, standard early-intervention and educational support services.
  • Genetic counseling: Recommended given autosomal dominant (typically) or, less commonly, autosomal recessive inheritance, particularly relevant for consanguineous families (NCIT:C15240, Genetic Counseling).
  • Experimental/mechanistic leads (preclinical only): Animal-model studies suggest that pharmacologic modulation of downstream pathways disinhibited by FGFR3 loss — Hedgehog/IHH pathway inhibition (PLOS Genetics 2015 mouse study) and Wnt/β-catenin inhibition (XAV939) (zebrafish 2020 study) — can partially rescue chondrocyte/skeletal phenotypes in model systems, representing potential future therapeutic targets, but these have not been tested in human CATSHL patients and no clinical trials for CATSHL specifically were identified.

No NCT-registered clinical trials specific to CATSHL syndrome were identified in this research; existing FGFR3-targeted therapeutics in clinical development (e.g., FGFR3 inhibitors, CNP-pathway analogs such as vosoritide) are designed for the opposite (gain-of-function, achondroplasia-spectrum) mechanism and are not applicable to CATSHL's loss-of-function pathophysiology.

13. Prevention

No primary, secondary, or tertiary prevention strategies exist beyond genetic counseling and prenatal/preimplantation genetic diagnosis for known familial variants in families with an established diagnosis, given the Mendelian (dominant or recessive) inheritance pattern. No immunization, screening program, or public-health intervention is applicable to this monogenic skeletal/auditory disorder.

14. Other Species / Natural Disease

No naturally occurring CATSHL-like disease has been reported in veterinary/companion-animal or wildlife populations in the literature reviewed. All non-human data derive from engineered laboratory models (see Section 15) rather than spontaneously occurring animal disease. FGFR3 is highly conserved between human and mouse, supporting cross-species mechanistic relevance, but no OMIA (Online Mendelian Inheritance in Animals) entry for a natural CATSHL-equivalent condition was identified.

15. Model Organisms

Model Genetic manipulation Key phenotype Reference
Mouse — conventional/conditional Fgfr3 knockout Targeted disruption of Fgfr3 Skeletal overgrowth (elongated long bones and vertebrae), kyphosis/scoliosis, crooked tails; profound deafness due to failure of pillar-cell differentiation and tunnel-of-Corti formation; short lifespan in the constitutive knockout Colvin et al. 1996, Nat Genet 12:390-397, PMID:8630492
Mouse — chondrocyte-specific conditional Fgfr3 knockout Cre-lox conditional deletion in chondrocytes Lengthened growth plates; significantly increased bone mass at 1 and 4 months; increased osteoblast number and bone formation; postnatal deletion produces chondroma-like lesions (enchondroma/osteochondroma) via decreased ERK/increased IHH signaling Zhou et al. 2015, PLOS Genetics, doi:10.1371/journal.pgen.1005214
Zebrafish — CRISPR/Cas9 fgfr3 loss-of-function Frameshift deletions in the tyrosine-kinase-domain-encoding exons (two independent stable lines) Microcephaly, domed skull, delayed cranial suture closure, mandibular/hyoid deformity, delayed endochondral and intramembranous ossification, chondroma-like growth-plate lesions, dysregulated swim bladder/Weberian apparatus development, reduced scale mineralization; enhanced Wnt/β-catenin and IHH signaling; partial rescue with Wnt inhibitor XAV939 Sun X. et al. 2020, Theranostics 10(16):7111-7130, PMID:32641982
Mouse — activating Fgfr3 Y367C (reciprocal gain-of-function model) Knock-in activating mutation (models Muenke syndrome/achondroplasia spectrum) Hearing loss and inner-ear defects from excessive FGFR3 signaling — informative as the mechanistic mirror-image control for CATSHL's hearing phenotype PMID:19073250

Phenotype recapitulation: The mouse and zebrafish Fgfr3 loss-of-function models recapitulate the core CATSHL triad of skeletal overgrowth, joint/growth-plate cartilage abnormality, and hearing impairment (via pillar-cell/organ-of-Corti defects) quite faithfully, and were instrumental in establishing FGFR3 loss-of-function as the causal mechanism — notably, the mouse phenotype was described a decade before the first human CATSHL family was reported, and the human discovery (Toydemir et al. 2006) explicitly drew on the mouse model to nominate FGFR3 as the candidate gene.

Model limitations: The zebrafish model captures craniofacial/microcephaly features not well recapitulated in mouse, but zebrafish skeletal architecture and organ of Corti biology differ substantially from human, limiting direct translational inference; mouse constitutive knockouts have reduced viability, complicating adult-phenotype study, motivating the shift to conditional/chondrocyte-specific models.

Applications: These models have been used to dissect the downstream signaling (MAPK/ERK, IHH/Hedgehog, Wnt/β-catenin) disinhibited by FGFR3 loss, and to test small-molecule pathway modulators (IHH inhibitors, XAV939) as proof-of-concept for future therapeutic strategies.

Summary of Key Evidence Citations

  • Toydemir RM, Brassington AE, Bayrak-Toydemir P, et al. "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome." Am J Hum Genet. 2006;79(5):935-941. PMID:17033969.
  • Makrythanasis P, Temtamy S, Aglan MS, et al. "A Novel Homozygous Mutation in FGFR3 Causes Tall Stature, Severe Lateral Tibial Deviation, Scoliosis, Hearing Impairment, Camptodactyly, and Arachnodactyly." Hum Mutat. 2014;35:959-963.
  • Cannova S, et al. "CATSHL syndrome, a new family and phenotypic expansion." Clin Genet. 2024;105:313-316. PMID:37990933.
  • Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3." Nat Genet. 1996;12:390-397. PMID:8630492.
  • Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. "Fibroblast growth factor receptor 3 is a negative regulator of bone growth." Cell. 1996. PMID:8601314.
  • Zhou X, et al. "FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling." PLOS Genetics. 2015. doi:10.1371/journal.pgen.1005214.
  • Sun X, et al. "Fgfr3 mutation disrupts chondrogenesis and bone ossification in zebrafish model mimicking CATSHL syndrome partially via enhanced Wnt/β-catenin signaling." Theranostics. 2020;10(16):7111-7130. PMID:32641982.
  • OMIM #610474 — CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME.
  • Orphanet ORPHA:85164 — Camptodactyly-tall stature-scoliosis-hearing loss syndrome.

Note on evidence gaps: No CATSHL-specific quality-of-life instrument data, no dedicated natural-history study, no CATSHL-specific clinical trial, and no naturally occurring veterinary disease model were identified — these represent open areas where the literature is silent rather than negative.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 10
Resolved 9
Unresolved (possible confabulation) 1
Unverifiable 0
References weighed for topical relevance 9
On topic 6
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.1371/journal.pgen.1005214](https://journals.plos.org/plosgenetics/article (1 mention) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 38
Resolved 37
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 16
Terms named correctly 8
Terms named as a different term 4
Terms whose name is worth a second look 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • CL:0002261 (1 mention) - the report calls it "Deiters' cell / cochlear supporting cell"; CL calls it endothelial cell of viscerocranial mucosa
  • UBERON:0002391 (1 mention) - the report calls it "cartilage of epiphysis / growth plate — approximate"; UBERON calls it lymph
  • UBERON:0004674 (1 mention) - the report calls it "organ of Corti / spiral organ"; UBERON calls it facial nerve root
  • UBERON:0002228 (1 mention) - the report calls it "rib cage / thoracic skeleton"; UBERON calls it rib

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:0007173 (1 mention) - the report calls it "epidermal growth factor receptor signaling pathway analog"; GO calls it epidermal growth factor receptor signaling pathway
  • GO:0060445 (1 mention) - the report calls it "branching involved in salivary gland morphogenesis – not relevant"; GO calls it branching involved in salivary gland morphogenesis
  • GO:0005007 (1 mention) - the report calls it "fibroblast growth factor-activated receptor activity"; GO calls it fibroblast growth factor receptor activity, and lists "fibroblast growth factor-activated receptor activity" among its other names
  • GO:0043235 (1 mention) - the report calls it "receptor complex"; GO calls it signaling receptor complex, and lists "receptor complex" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.